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(1) Nutritional status is impaired in symptomatic congenital heart disease (CHD) in
infancy, and this is related to an inadequate positive energy balance. (2) Undernutrition
precedes the development of bronchopulmonary dysplasia (BPD) in preterm infants, and
there is a subsequent persistent deficit in energy balance, bone mineral content (BMC)
and growth.
Objectives
To study (1) the effect of CHD on growth and energy balance in infancy (2)
macronutrient intake prior to the development of BPD (3) the effect of BPD on energy
balance and BMC and the effect of dexamethasone used to treat BPD on BMC.
Background
Poor growth is seen commonly in chronic disease of the heart and lungs (CCPD) and is
important because: (a) the disease and its treatment may compromise nutrition (b) good
nutrition may influence the outcome of the condition and adult health. Body growth in
infants is dependent upon a sufficiently positive balance of protein and energy, and
certain micronutrients are important for aspects of specific organ development. There are
few previous studies looking at specific aspects of nutrition in young infants with CCPD.
Methods
CHD Energy balance measurements were carried out on 21 infants with CHD, post-term
age [median (range)] 49 days (-9 to 246) and in 9 controls, post-term age 35 days (-14 to
86). Energy intake (EI) and losses (EL) were measured by bomb calorimetry (18 CHD, 5
control), resting energy expenditure (REE) by indirect calorimetry over several hours (14
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CHD, 9 control), and anthropometry performed. Metabolizable energy intake (MEI) was
calculated as EI-EL, and energy available for deposition (EAD) as MEI-REE.
BPD 195 consecutive infants of <32 weeks gestation had weekly anthropometry and
records of achieved nutritional intake. 54 of these had dual energy X-ray absorptiometry
of the forearm for bone mineral content (BMC). Case control studies were done on nested
cohorts within this group: (1) macronutrient intake and growth in 20 babies with BPD
and 20 gestation and birthweight matched controls, (2) BMC in 10 babies with BPD and
10 gestation and birthweight matched controls, (3) BMC in 15 BPD babies treated with
dexamethasone and 15 untreated BPD controls. In a separate convenience sample of 4
infants with BPD and 4 preterm controls El and EL were determined by bomb
calorimetry.
Results
CHD There was a fall with age in z-score for body size: for weight 1SD in 21 days,
length 1SD in 43 days and head circumference 1SD in 37 days. Weight gain over 5 days
[median (quartiles)] was less in cardiac infants [ll.Og/d (2.5-16.7)] than in controls
[39.0g/d (20.0-47.5)], P=0.0034. There was no statistically significant difference in EI,
EL, or MEI between the groups. Sleeping oxygen uptake [SV02, median (range)] was
similar in CIID infants [9.93ml/kg/min (7.7-13.88)] and controls [9.23ml/kg/min (7.5-
11.66)], with the highest values in 3 of 4 infants with persistent cardiac failure and
pulmonary hypertension. Respiratory quotients were similar. SVo2/kg correlated
inversely with log [summed skinfold thicknesses] (r2=0.671; P=0.0001) and with body
mass index. There was a positive correlation in CHD infants between weight gain and
MEI %RDA (r2 =0.28, P=0.024), and energy available for deposition (r2 =0.43, P=0.05).
BPD BPD infants had lower early macronutrient intake than controls [median
(quartiles)]: for first week EI, BPD = 262 kJ/kg/d (210-282), control = 347 kJ/kg/d (293-
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372), P=0.003. BPD infants had a lower proportion ofEI as enteral feeds than controls in
the first 2 weeks [median (quartiles)]: BPD = 68% (31.3-79.2), control = 91% (78.0-
93.0), P=0.0025. The rate of weight gain [slope (95% CI)] was less in babies with BPD
[151.5 g/week (135.5-167.6)] than in controls [192.2 g/week (178.5-205.9)], P<0.05.
There was no demonstrable difference in z-score values for weight, length, head
circumference or body mass index at discharge. In the small sample studied, there was no
difference in EI, EL, or MEI. For MEI, BPD = 592 kJ/kg/d (425-741), control = 565
kJ/kg/d (527-737). For all babies measured (n=54), BMC at birth [median (quartiles)]
was 1.79mg/mm (1.57-2.03), with a fall in the first 5 weeks by 0.23mg/mm (0.09-0.41),
followed by a rise, with a value at 10 weeks of 1.99mg/mm (1.69-2.16). There was no
detectable difference between the BPD and control groups. Dexamethasone had no effect
on the postnatal trend in BMC, but was associated with slower forearm growth: length
increase in 5 weeks [median (quartiles)] for steroid group =7.54mm (0.6-7.6), for
controls =11.6 (5.4-24.5), P=0.019.
Conclusions
CHD There appears to be a progressive postnatal deterioration of nutritional status in
hospitalized infants with CHD. This is associated with a tendency to lower energy intake,
and in addition raised REE in some infants. Availability of energy appears to be a
limiting factor for growth in this group.
BPD There is a shortfall of nutrient intake in the first two weeks, particularly via the
enteral route, in preterm infants who later develop bronchopulmonary dysplasia. The
subsequent rate ofweight gain is slower for several weeks in these babies. There appears
to be no abnormality of energy intake or losses. There is a large deficit in BMC in
preterm infants at term, with no additional effect of BPD. Systemic steroid treatment
slows linear growth, without any apparent effect on bone mineralization.
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1.1 NUTRITION AND GROWTH IN CHRONIC DISEASE
Many chronic diseases are associated with physiological changes which result in
impaired nutritional status. In some of these diseases, undernutrition may adversely affect
the progression of the condition. In chronic cardiopulmonary disease (CCPD), gross
protein-energy insufficiency might impair respiratory muscle strength and function, and a
shortfall of certain micronutrients might adversely affect myocardial and pulmonary
function (Anker and Sharma 2002, Schols 2002). There are additional potential costs of
undernutrition in early life. Poor nutrition in the first few months of life may compromise
brain growth and maturation (Dobbing 1981). Poor body growth is a common feature of
chronic disease in childhood, and its degree often relates to the severity of the underlying
condition. Small size may affect the older child's psychological adjustment, and delay the
onset of puberty (Ehlers 1978, Linde et al 1967). In addition, there is accumulating
evidence that early nutrition influences the development of adult disease (Lucas 1990).
This is of growing relevance, since with improvements in care the life expectancy of
sufferers from chronic disease is increasing.
There has been much controversy about the mechanisms causing impaired
nutrition in various chronic conditions. Is inadequacy of nutrient intake or retention the
primary cause, or are metabolic alterations to blame? Into the latter category fall
endocrine changes resulting in increased basal metabolism, and increased work of the
heart and breathing. If there are metabolic changes, are these related to a basic cellular
abnormality present at birth, or are they the result of correctable anatomical or
physiological abnormalities related to the underlying condition? The syndrome of
cachexia in chronic disease, which has been recognised for some time, is now seen to be
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the result of a complex combination of endocrine, inflammatory and other influences in
addition to poor intake (Conraads et al 2002).
There are many theoretical reasons why undernutrition may exacerbate some
disease processes, and there is reason to believe that in some conditions improving
nutritional intake can reduce disease severity (for example, Borowitz 1996).
Key to the study of nutrition in chronic disease is the assessment of nutritional
status. Nutritional status can be studied in one of three main ways: (a) measurement of
body composition (by anthropometry as well as by more sophisticated techniques) -this
provides a static assessment of nutritional adequacy which can be compared to
measurements in healthy children, although the mechanisms of undernutrition cannot be
elucidated in this way (b) assessment of nutrient balance -measuring the intake and
output of energy and protein, for example (c) measurement of a bodily function which is
dependent upon the adequacy of one or more nutrients.
Two groups of chronic conditions will be considered here (a) congenital heart
disease (b) bronchopulmonary dysplasia, or chronic lung disease in preterm infants.
1.2 NUTRITION AND GROWTH IN CONGENITAL HEART DISEASE
1.2.1 Growth in congenital heart disease
It has been recognized for some time that children with congenital heart disease
(CHD) are frequently small for their age. Mehrizi and Drash (1962) demonstrated the
extent of the problem in a large study, which showed that nearly one third of such
children of all ages were below the third centile for weight and height. Evidence of
undernutrition is present in a high proportion of children hospitalized with congenital
heart disease (Cameron et al 1995).
10
Corrective surgery is the ultimate aim, and may be the best ultimate solution to
poor growth in CHD. Advances in surgical technique have made complicated surgery
possible in younger infants. However, surgery may have to be delayed, and may be more
hazardous in undernourished or ill children (Haydock and Hill 1986).
The evidence from the literature suggests that a large number of factors, prenatal
and postnatal, may contribute to growth retardation in CHD.
(i) Prenatal growth
The birthweight of infants with CHD is not, as a whole, significantly different
from that of normal infants (Mehrizi and Drash 1962, Feldt et al 1967, Suoninen 1971).
Levy et al (1978), however, found an increased incidence of light-for-dates babies in
"severe" CHD.
Suoninen (1971) found a higher incidence of prematurity in CHD, mainly in
infants with patent ductus arteriosus. In this condition, it is obviously possible that
prematurity was, in some cases, contributing to the continuing patency of the ductus.
A subgroup of infants with CHD is born small for gestational age with
malformation syndromes, including those resulting from genetic abnormalities and from
intrauterine infection (Jackson 1968). In these, growth impairment is likely to be due to a
primary defect in morphogenesis affecting many tissues of the body, and is less likely to
benefit from therapeutic measures (Shelton 1980).
A recent large epedemiological study suggested that there were differences in
body proportions at birth in certain types of congenital heart disease unassociated with




Many studies have documented the postnatal growth of children with CHD. They
vary enormously in the size of the population studied, criteria for selection of cases, the
grouping of children in disease categories, and the definition of growth impairment.
Some of the earliest published studies, by Adams et al (1951 and 1954) showed
large variations in the growth of children with CHD, the most consistently small being
those with left to right shunts. They also demonstrated some postoperative improvement
in the growth of children who had a patent ductus ligated, soon after this operation was
first introduced.
A summary of some of the findings of other studies is as follows:
Weight is usually affected more than height (Linde et al 1967, Miller et al 1969,
Suoninen 1971). Boys are affected more severely than girls in most lesions (Linde et al
1967, Suoninen 1971). There is often acceleration in growth, particularly in weight, after
surgery (Umansky and Hauck 1962, Feldt et al 1969, Suoninen 1971), although this is not
always the case (Maxwell 1966). Body size is usually closer to normal at adolescence,
whether there has been surgical intervention or not (Linde et al 1967).
Clinical parameters of growth other than weight and height have not been well
documented in these children.
(iii) Causes of poor growth
Many hypotheses have been put forward to explain postnatal growth retardation in
CHD. Approaches to investigation have been equally diverse, and clear conclusions
cannot be drawn from the literature.
The main hypotheses fall into the following categories, which are obviously not
mutually exclusive: (1) familial or hereditary factors (2) haemodynamic abnormalities
12
(3) cellular abnormality (4) endocrine changes (5) recurrent infection (6) undernutrition
(7) hypermetabolism.
(1) Familial or hereditary factors The siblings of undersize children with CHD
show a normal distribution of weight and height (Maxwell et al 1966, Linde et al 1967).
Thus familial small size is probably not important. Jackson (1968) suggested that
recognizable chromosomal anomalies were associated with 3 to 5% of cases of CHD;
also that recessive or polygenic inheritance may be important. Small size may, of course,
be part of such a genetic syndrome.
(2) Haemodvnamic abnormalities These may be expected to cause poor growth
for several reasons: (a) poor peripheral systemic blood flow in children with heart failure,
and tissue hypoxia and acidosis resulting in poor peripheral utilization of nutrients (b)
impaired food intake due to respiratory embarrassment and anorexia (c) malabsorption
due to venous congestion and/or hypoxia of the bowel (d) increased work of the heart and
breathing, leaving less energy for growth.
Few clear-cut correlations have been found between the presence or severity of
haemodynamic abnormality and the degree of growth retardation. The most seriously
retarded group in most studies is that with cyanotic conditions (Mehrizi and Drash 1962,
Linde et al 1967, Suoninen 1971). However, no relationship seems to exist between the
degree of arterial hypoxaemia and the degree of growth retardation (Feldt et al 1969,
Linde et al 1967, Suoninen 1971). Of the acyanotic group, children with VSD causing
heart failure in infancy were severely affected (Feldt et al 1969). Miller et al (1969) found
no good correlation between any haemodynamic values and growth failure in VSD,
although there was some association between pulmonary hypertension and poor weight
(3) Cellular factors Study of muscle specimens in children with CHD has shown
a reduction in cell number in relation to age, and probably in relation to height (Cheek
1968). In post-mortem studies (Naeye 1967), those who died in the perinatal period had
cellular changes suggestive ofmild intrauterine growth retardation; those who died aged
1 month to 8 years showed changes suggestive of chronic undernutrition; those who died
later had abnormalities related to chronic hypoxia. Adipose tissue cellularity is reduced in
children with cyanotic CHD (Baum and Stern 1977), suggesting that hypoxaemia affects
adipocyte multiplication in infancy.
(4) Endocrine changes Hait et al (1972) demonstrated abnormal oral glucose
tolerance with high blood sugar values and low insulin response to hyperglycaemia in
infants with congestive cardiac failure. They suggested that this may be due to high
circulating catecholamine levels suppressing insulin, or secondary to protein-calorie
malnutrition, which is known to cause abnormal carbohydrate metabolism, with impaired
insulin response to glucose (Becker 1983).
Another study (Gacs et al 1971) suggested low blood sugar levels in cyanotic
children, possibly related to decreased release from glycogen in the liver. The same
authors showed normal fasting levels of adrenal corticosteroids and growth hormone
response to insulin stress in cyanotic children.
(5) Infections It has been suggested that frequent infections, especially of the
respiratory tract, contribute to growth retardation in CHD. Suoninen (1971) found a
positive correlation in coarctation of the aorta only. Maxwell et al (1966) did not find any
link.
(6) Undernutrition and (7) Hypermetabolism Undernutrition may be one common
pathway by which many of the abnormalities described above result in growth
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retardation. As stated previously, post-mortem changes reminiscent of chronic
undernutrition are found in many instances.
There are several reasons, in theory, why growth retardation in CHD may be
associated with undernutrition. In general terms, normal postnatal growth requires an
adequate supply of structural elements for tissue synthesis (e.g. proteins), of energy (the
energy cost of growth), and certain micronutrients required as cofactors for normal
metabolism.
An inadequate supply of any nutrient may be due to (a) poor intake (poor feeding,
vomiting) (b) poor intestinal absorption (c) poor peripheral utilization (due to
haemodynamic disturbances) or (d) increased utilization resulting in increased demand.
Little work has been done on nitrogen balance in CHD. Iber et al (1967) found
somewhat increased stool albumin losses, but a markedly positive nitrogen balance in the
face of poor growth in a small number of infants. They suggested increased insensible
loss of nitrogen, possibly as free nitrogen gas in expired air. This finding may merely
reflect the tendency inherent in balance studies to underestimate nutrient losses and thus
overestimate nutrient retention (Hegsted 1976).
There may be inadequate energy substrate to supply the energy cost of growth,
which is a combination of the energy stored in the components of new tissue and the
energy used in the anabolic processes of tissue synthesis (Widdowson 1961). It is one
component of the energy balance of an individual, which is the main subject of the
present study.
1.2.2 The Principles of Energy Balance
The concept of "energy balance" is a specific application of the Law of
Conservation of Energy. There is every reason to believe that it is as applicable to a
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biological system as to a physical one. Thus, there is no net energy gain or loss from a
closed system, but there may be conversion of energy from one form to another.
An energy balance equation can be written for an individual as:
r
Energy ingested




(metabolism incl. heat loss)
+ Energy losses (in stools, urine and vomitus)
+ Energy stored in new tissue
v
Gross or thermochemical energy is the energy released by complete oxidation of a
food substance, and is usually measured using a bomb calorimeter.
(i) Total energy expenditure
In a thermoneutral environment (when energy does not need to be expended for
thermoregulation),





(including energy used for tissue synthesis)
+ Diet-induced thermogenesis + Energy used in activity
In adults, "resting energy expenditure" becomes "basal energy expenditure" after
a period of fasting (usually 12 hours), when dietary thermogenesis is no longer
significant. This cannot ethically be measured in young children.
(ii) Energy cost of growth and metabolizable energy intake
The energy cost of growth comprises the chemical energy stored in new tissue
together with the portion of total energy expenditure used to fuel growth.
Energy cost of growth = Energy stored in new tissue + Energy used for tissue synthesis
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The energy cost of growth has to come from that part of ingested energy available
to the body allowing for losses in vomitus, stool, and urine, that is metabolizable energy.
Metabolizable energy = Ingested energy - losses in vomitus, stool and urine
(MEI) (EI) (EL)
The energy available for deposition will, in theory, be reduced if (a) ingested
energy is reduced (b) energy losses are increased in stools, or by vomiting or in the urine
or (c) energy expenditure is increased.
(iii) Special considerations in childhood
Evidence, mainly from cross-sectional data, suggests that energy expenditure
expressed per kg body weight increases during the first 2 years of life (Schofield 1985).
During this time the contribution of physical activity increases. Overall, values then fall
towards adulthood, an important cause of this change being a fall in the relative
contribution to body weight by metabolically active organs (particularly brain, liver,
kidneys and heart which together form 19.5% of body weight in the newborn and 4.9% in
the adult, Holliday 1971). In infancy, rapid growth and the different quality and frequency
of feeding probably also contribute to higher energy expenditure.
1.2.3 Methods available for investigating energy balance
The experimental study of energy balance involves the accurate determination of
ingested energy, and of losses in stool, urine, and vomitus, and the measurement of
energy expenditure. The energy available for deposition has to be derived from these,
(i) Energy Intake and Losses
Measurements of intake and losses is, in many ways, easier to perform in young
infants, since their diet consists of milk alone, and their limited mobility enables the
easier collection of excretory products and measurement of metabolic rate.
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Metabolic cradles, which restrain infants and thus make the complete collection and
separation of excretory products possible, are non-physiological and cannot, for obvious
reasons, be used for prolonged periods.
Several careful studies have been done in neonates, including those of low birth
weight, with little disturbance to their normal activities (Brooke et al 1979, Reichman et
al 1982). Little work has been done in older infants or in children with CHD.
Over several days, milk intake is measured, and accurate timed collections made of
vomitus and excreta. The energy content of food and excreta is derived from either (a)
chemical analysis of their carbohydrate, fat and protein content, and subsequent
calculation of energy values using energy conversion factors (e.g. Atwater factors)
derived from measurements of metabolizable energy, or (b) measurement of their heat of
combustion in a bomb calorimeter, giving a value for gross or thermochemical energy
(Miller and Payne 1959). The thermochemical energy value of a food is higher than the
calculated metabolizable energy, which takes into account incomplete absorption and
incomplete oxidation of protein.
In nutrient balance studies there is a bias towards overestimation of intake because
of failure to take account of all spillages and regurgitations, and towards underestimation
of losses because (a) collection of stools, urine and vomitus may be incomplete (b) losses
in shed skin and in sweat are usually ignored. This leads to an overall bias towards
overestimation ofmetabolizable energy intake (Hegsted 1976).
(ii) Energy expenditure
Energy expenditure (EE) has, traditionally, been measured by direct or indirect
calorimetric methods.
(1) Direct and indirect calorimetry Direct calorimetry involves the measurement
of the heat produced as a by-product of metabolism, in a chamber made of materials of
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accurately known specific heats. The equipment needed is costly and complicated to use,
and this type of method is little used in clinical research.
Indirect calorimetry involves the measurement of some variable, other than heat
production, directly related to energy expenditure. Examples include heart rate (Spady et
al 1976), evaporative water loss (Puyau 1969, Kennaird 1976), and respiratory gas
exchange. Stable isotope techniques developed more recently, although indirectly
measuring gas exchange, are usually considered separately.
(2) Respiratory gas exchange This method of measuring energy expenditure was
predicted by Lavoisier, who recognized that an animal's oxygen consumption (V02) and
carbon dioxide output ('VCo2) depended upon activity, food and temperature. It is based
upon the assumption that the metabolic processes contributing to energy expenditure use
oxygen and produce carbon dioxide in a completely aerobic and predictable way.
In theory, gas exchange can be measured very accurately by analysis of inspired
and expired gases. Energy expenditure is then calculated as follows (Davson and
Eggleton 1968):
(a) Measure oxygen consumption, carbon dioxide output and urinary nitrogen
excretion (as a measure of protein metabolism).
(b) Calculate the respiratory quotient (RQ, carbon dioxide output/oxygen uptake),
which is dependent upon the mixture of substrates utilized. The use of carbohydrate alone
(most commonly glucose, derived from other carbohydrates or by gluconeogenesis from
fats or amino acids) results in an RQ of 1.00; fat metabolism gives an RQ of near 0.7; and
protein around 0.8.
(c) Derive non-protein V02, VCo2 and non-protein RQ from total V02, VCo2, RQ
and urinary nitrogen, taking into account the fact that protein is incompletely oxidised
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(published tables) - this provides an indication of the proportion of fat and carbohydrate
metabolised.
(d) Calculate energy expenditure from tables of energy value per litre oxygen at
different levels of non-protein RQ (Zuntz and Schumberg, mod. by Lusk, mod. by
McClendon, in Harper et al 1979). This value ranges from 19-21 kJ per litre of oxygen
consumed in the range ofRQ 0.7-1.0.
Several studies have measured oxygen uptake alone and used an assumed RQ.
This would lead to a maximum error of about ±3% within the physiological range of RQ.
If urinary nitrogen excretion is not measured, the maximum associated error is
3.2% (see Appendix).
In practice, a large variety of techniques has been developed for the measurement
of respiratory gas exchange. There has been little standardization of techniques, even
within the paediatric age group, and with some techniques little validation.
(3) Open and closed circuit methods There are two main types of method for
measuring gas exchange directly: (a) open circuit, (b) closed circuit. In a closed circuit
system, the subject is contained in a chamber which forms part of a closed system
through which air recirculates. Carbon dioxide is absorbed out and measured; oxygen
uptake is measured either as the decrease in the volume of the system, or the amount of
oxygen which has to be added to keep the volume of the system constant. Such a system
needs to be strictly airtight, and gas concentrations and temperatures precisely controlled;
volume changes need to be measured accurately. This makes the method complicated and
expensive. Access to the subject is not possible, and studies can therefore only be
performed over short periods.
An open circuit method was first described by Pettenkofer and Voit (1862). This
type of method is much more versatile, and always involves the subject breathing in a
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moving, continuously replenished stream of air. With the subject inside a chamber,
Pettenkofer described the carbon dioxide output of an animal as:
C02 output = airflow x C02 concentration difference in entry and exit gases.
To be entirely accurate, oxygen and carbon dioxide concentrations in, and flow
rates of incoming and outgoing air streams need to be measured. Then,
C02 output = (Flow out x C02 conc. of air out) - (Flow in x C02 conc. of air in)
In practice this can be simplified by assuming that there is no difference between
the two flow rates (for errors involved see Appendix):
C02 output = Flow out x insp.-exp. conc. difference of C02.
Identical equations, substituting 02 for C02, can be used for oxygen uptake.
The earliest open circuit measurements of gas exchange involved the accurate
collection and later chemical analysis of expired gases. This made the equipment
unwieldy and complicated to use. The availability, more recently, of instruments capable
of automatic, continuous gas analysis, has made open circuit systems more flexible.
Open circuit systems have in common a pump to draw air through the circuit, a
flow meter, and an oxygen analyser (with or without a carbon dioxide analyser). They
differ mainly in the way in which they interface with the subject. This varies from a
funnel or facemask held over the child's face, to a headbox, or a whole body chamber in
which the child is enclosed.
Masks and headboxes provide a small dead-space. This means that large flow
rates need to be used to prevent re-breathing of carbon dioxide, and sensitive gas
analysers are needed to detect changes in concentration of the very diluted gases. Also,
although theoretically, breath-by-breath changes in gas exchange can be recorded with
little damping, this is not necessary for most purposes, and a more averaged recording
showing major changes is more useful. Workers who have used such a method have
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usually added some mechanical or electronic damping device, for this reason. Masks and
headboxes restrain infants, and may by their presence alter the child's breathing pattern.
They are therefore only suitable for short-term measurements of sleeping gas exchange,
and for use with sedated children, for example during cardiac catheterization. Whole
body chambers provide some freedom of movement for the infant, and because of the
dead space, some damping of changes in expired gas concentration.
(4) The influence of thermal environment The thermal environment (a concept
which includes ambient temperature, its gradient with skin temperature, air humidity,
clothing and radiant and convective stresses) has a significant influence on energy
expenditure in infancy. The neutral thermal environment is one in which metabolic rate
and evaporative heat loss are at a minimum. Cold stress increases metabolic rate by
invoking non-shivering thermogenesis (mainly in brown fat) and shivering (Bruck and
Wunnenberg 1966). It also causes vasoconstriction, which results in skin cooling in the
acral areas. Overheating may affect metabolic rate by eliciting behavioural responses
(Harpin et al 1983). It has been suggested that the optimal thermal environment may be
different in babies with congenital heart disease (Kennaird 1976).
(5) Resting and Total Energy Expenditure Energy expenditure is usually
measured with a view to calculating the energy requirements of an individual or group. In
order to do this REE alone cannot be used and TEE needs to be estimated. Thus, either a
correction has to be made for activity and thermogenesis, or TEE itself needs to be
measured. In some conditions associated with an increased REE, there appears to be a
balancing reduction in energy expended in activity (Macallan et al 1995), thus leading to
incorrect extrapolation from REE to energy requirements.
Many indirect calorimetric studies have used measurements of gas exchange of
short duration during sleep, to derive resting metabolic rate. Stothers and Warner (1978)
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found that in the neonate, oxygen consumption varied in different sleep states. In
nutritional studies, measurements of longer duration with the subject in different states of
wakefulness enable total energy expenditure to be derived more precisely. Several such
prolonged studies have been performed in low-birthweight neonates, (e.g. Chessex et al
1981, Gudinchet et al 1982, Abdulrazzak et al 1983), but few in larger infants or in CHD.
Methods used to calculate gas exchange and derive energy expenditure values from these
involve certain assumptions and vary enormously in complexity in the literature.
Since the early 1990s stable isotope methodology, which allows measurement of
TEE in free-living subjects, has taken increasing prominence in energy balance research.
(6) The doubly labelled water method In the most widely used stable isotope
method, doubly labelled water (water enriched with the naturally occurring stable
isotopes deuterium or 2H, and l80) is ingested by the subject. CO2 production is then
derived from the difference in rate of disappearance of the two isotopes from the body
water pool (2H being incorporated into water, and l80 into water and CO2). This
technique can be used in free-living subjects without interfering with normal activity and
environment, and is used to derive total energy expenditure, assuming the respiratory
quotient.
A body of work from the Dunn Nutrition Unit in Cambridge, UK, has added
considerably to the literature on energy expenditure in infancy and has challenged
traditional thinking on energy balance. These studies used the doubly labelled water
technique to estimate total energy expenditure and body composition, in addition to
traditional indirect calorimetry and anthropometry.
This work has suggested significantly lower energy requirements for infants and
children than had been recommended in the past (Davies et al. 1995, Davies et al. 1997).
Furthermore, in healthy subjects there appeared to be no relationship between fatness in
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childhood and (a) total energy expenditure or behaviour in infancy (Wells, Cole et al.
1996; Wells, Stanley, et al. 1996; Davies et al 1991) or (b) milk volume or energy intake
in infancy (Wells, Stanley et al. 1998).
Using stable isotope techniques to estimate total energy expenditure and fat free
mass simultaneously, Davies et al showed that fat free mass is the best corrector for body
size for the purposes of expressing energy expenditure in young infants. Even after
allowing for this, small for gestation infants appeared to have higher energy expenditures
for a given fat free mass (about 20% more) than appropriately grown infants (Davies et
al. 1996). Body weight0 5 appeared to provide a reasonable estimate of metabolic body
size in healthy infants (Wells & Davies 1995).
There were differences in sleeping metabolic rate measured by indirect
calorimetry between breast and formula fed babies, which appeared explicable by
differences in FFM, but in addition a gender difference which appeared independent of
FFM. With age and growth there is a change in the metabolic activity per gram of fat free
mass, because of an increase in the contribution of muscle (metabolically relatively
inactive) compared to other organs (relatively active). In addition, there is a reverse in the
relative contributions of physical activity (increasing) and growth (decreasing) to energy
expenditure with age in the first year (Wells & Davies 1998).
Assumptions are made during stable isotope studies about isotope dilution spaces.
These change with age in healthy children (Wells, Ritz, et al. 1998), mainly as a result of
a reduction in percentage of body water, and are likely to be affected by various disease
states. Thus equations used to derive energy expenditure using assumptions based on
healthy children will need to be modified when studying children with cardiac failure in
whom there are basic changes in body fluid compartments which may alter further with
drug therapy (Mitchell et al. 1994).
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1.2.4 Energy balance in chronic disease
Insights into the interaction between chronic disease and nutritional status can be
gained from the body of recent literature on the nutritional consequences of cystic fibrosis
and human immunodeficiency virus disease. This literature also illustrates the difficulties
of performing and interpreting studies of energy metabolism in chronic disease.
Cystic fibrosis is associated with a progressive deterioration in growth and
nutritional status throughout childhood. Malnutiition is an adverse prognostic factor, and
avoiding it may improve outcome (Levy et al 1985). A negative energy balance is central
to malnutrition in cystic fibrosis, as in many chronic diseases, although there is debate
about the role of different components of energy balance (Reilly et al 1997). The
inflammatory process may play a role in the pathogenesis of malnutrition, particularly
through the influence of cytokines, which are associated with anorexia and
hypermetabolism (Bell et al 2000).
Decreased EI, increased EE, impaired digestion and absorption, and excessive
losses might all contribute to a negative energy balance in cystic fibrosis (Reilly et al
1997). Short periods of very low intake, particularly with intercurrent infection, as well as
sustained subnormal intake probably play a large part in malnutrition in this condition.
Fat digestion is suboptimal, even with good pancreatic supplementation. Undigested
carbohydrates, normally reabsorbed after fermentation by colonic bacteria, appear
unchanged in the stool. Many studies have shown increased REE, but this does not
necessarily equate to increased TEE. This may be due to a "compensatory" decrease in
activity. The contribution of a genetic component to hypermetabolism is unclear despite a
large number of studies on this subject. There is a close inverse relationship between
REE and lung function; REE is not raised in those with good lung function and
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nutritional status. The link between lung function and REE may be related to (1) the cost
of tissue synthesis related to protein turnover (2) the energy cost of breathing (3) beta-
agonist treatment increasing REE (4) mild chronic inflammation or infection - this may
be mediated by cytokines (anti-inflammatory drugs have been shown to promote weight
gain). Hypermetabolism during acute pulmonary exacerbations may cause a cumulatively
negative energy balance. The increased REE appears to be balanced by a reduction in
physical activity, except in moderate to severe lung disease, when the compensation may
not be complete. Interestingly, the relationship between TEE and weight loss in HIV
infected subjects is the opposite of that expected -wasted patients have a low TEE
(Macallan et al 1995). One possible explanation is that the energy cost of particular
activities may be altered as part of the disease process.
1.2.5 Energy balance in congenital heart disease
(i) General issues
In heart disease, there are several theoretical reasons why energy balance may be
affected (1) intake may be reduced because of anorexia, reduced respiratory reserve, and
a feeling of fullness because of slow gastric emptying (2) losses may be increased
because of (i) malabsorption because of hypoxia or venous congestion of the bowel or (ii)
increased vomiting (3) expenditure may be increased. Pittman and Cohen (1964) stated
that a diseased adult heart may use up to 30% of the body's oxygen uptake for its
metabolism, as opposed to 10% in a normal heart. It should be remembered that in the
infant the partitioning of energy expenditure is very different to that in the adult, the
organs contributing a greater proportion of energy expenditure, thus making any increase
potentially more significant. It has been suggested that individuals with heart failure have
an increased sympathetic drive (Chidsey and Braunwald 1965, Lees et al 1965). The
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sympathetic nervous system stimulates brown fat metabolism which, some believe, plays
a key role in controlling metabolic rate (Rothwell and Stock 1981).
(ii) The literature
The published evidence about energy balance in CHD is conflicting, but is
summarized below.
In infants, a subnormal ingested energy in relation to weight has been
demonstrated (Kreiger 1970, Huse et al 1975). Another study showed adequate energy
and nutrient intake in older children (Strangeways et al 1978).
Forced feeding (Kreiger 1970) or continuous or overnight tube feeding
(Vanderhoof et al 1982, Schwarz et al 1990) improved anthropometric measures.
Cavell (1981a and b) performed studies of gastric emptying using a tracer in the
feed and measuring its disappearance from gastric residuals. They showed that gastric
emptying was slower in infants with heart disease, and suggested that this might cause a
feeling of fullness, leading to reduced food intake. Adding a glucose polymer to increase
energy density, despite further decreasing gastric emptying, increased the throughput of
calories into the small intestine (measured as disappearance from the stomach). However,
energy retention was not measured, and in fact one infant developed diarrhoea
presumably because of an osmotic effect.
Intestinal absorption has not been well studied in CHD. Sondheimer and
Hamilton (1978) found excessive intestinal protein loss in some children, though not to
the extent seen in conditions associated with malabsorption such as coeliac disease. No
other consistent digestive tract abnormality was found, in particular there were no
abnormalities on intestinal villous biopsy. Vaisman et al (1994) found no overall increase
in stool fat or energy losses in infants with congenital heart disease treated with diuretics,
but found an association between losses and total body water in these babies.
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Energy expenditure in CHD has been assessed mainly by measuring respiratory
gas exchange. This has usually been done over short periods with the child asleep or
sedated. As well as helping in the study of energy balance, it is useful to the cardiologist
for the calculation of cardiac output and systemic and pulmonary blood flow, from
variables measured at cardiac catheterization.
Some workers have found increased resting metabolic rate in relation to weight in
CHD (Lees et al 1965, Stocker et al 1972, Kraus and Auld 1975). Others found it was
normal (Cheek 1968, Huse et al 1975). The infants with higher metabolic rates were
often the most undernourished in these studies. However, expressing EE per unit body
weight rather than per unit fat free mass (a more recent practice) will tend to give higher
levels in thin babies because of their greater proportion of metabolically active lean
tissue. In one study (Kennaird 1976), acyanotic conditions were associated with an
abnormally high metabolic rate, and cyanotic conditions with a subnormal rate. In the
latter, metabolic rate was increased when surgery removed the cyanosis. The author
suggested that the thermoneutral range of temperature resulting in minimal oxygen
consumption was different from normal in cyanotic babies (higher) and acyanotic babies
in heart failure (lower).
A study using the doubly labelled water method showed a significant increase in
total daily energy expenditure with lower than expected intake in infants with CHD
(Barton et al 1994). In another study children between the ages of 4 and 33 months were
studied before and after cardiac surgery (Mitchell et al 1994). In nearly 30% of cases
there was a significant elevation of energy expenditure, which fell to within the normal
range immediately postoperatively.
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(iii) Difficulties with interpretation of the evidence
The literature on energy balance in childhood and in CHD needs cautious
interpretation for the following reasons:
(a) The populations studied are of widely different age ranges and cardiological
diagnoses. It is important to take the age of subjects into consideration, independently of
body size, because the apportionment of ingested energy to the different components of
energy balance changes markedly with age. This is particularly true of the proportion of
ingested energy used for growth; it decreases from about lA of ingested energy up to the
age of 2 months, to less than 5% after 5 months (based on normative growth data and
assuming a constant energy cost of growth).
(b) Until recently, there has been a paucity of normative data on energy balance,
and it has been difficult to obtain control subjects for such studies. The normal data
available relates mainly to neonates and young infants. Energy balance has been studied
in detail in neonates of low birthweight (e.g. Brooke et al 1979, Reichman et al 1982),
but not so much in older infants. Fomon (1971) measured the voluntary intake of full
term newborn infants fed a cow's milk formula. Recommended dietary allowance (RDA)
values have been based, in the past, on such studies of observed intake (DHSS 1979).
More recently, energy requirements in infants have been calculated from measurements
of energy expenditure using the doubly labelled water technique added to an estimate of
stored energy (with knowledge of the rate of weight gain and the body composition of
reference infants of different ages) (Davies, Ewing et al 1989, Prentice et al 1988). These
results suggest that older methods had overestimated requirements by 42-46kJ/kg/day in
infants up to 6 months.
(c) The methods used vary widely, especially in the measurement of metabolic
rate. These will be discussed later.
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(d) In most studies, only selected aspects of energy balance have been measured,
and over relatively short periods of time.
(e) There is disagreement about the best way to present data. A special difficulty
is the issue of relating energy balance to measures of body size.
In nutritional studies, comparison needs to be made between individuals of
different sizes and states of nutrition. Thus energy balance values should be expressed in
terms of some aspect of body size enabling direct comparison. Weight has been used in
most clinical studies (e.g. kJ/kg body weight). The criticism of this is that the body
composition of a growth-retarded child is very different from that of a normally grown
child. Specifically, a growth-retarded individual has a larger proportion of lean tissue,
which is metabolically more active than adipose tissue, and this may result in an
artificially high value for metabolic rate when related to weight.
Lean body weight would be a logical choice, but is technically difficult to
measure. Nutritionists have tried, mathematically, to derive measures relating to this.
3/4
Kleiber (1961) thought that the measure "weight " enabled comparison of energy values
between individuals ofwidely varying sizes (for example, a mouse and an elephant). It is
felt that this may be less applicable to individuals within a narrower range of size (e.g.
different human individuals) (Davies, Cole et al 1989). More recently fat free mass has
been derived using techniques such as stable isotope measurement of total body water,
total body electrical conductivity (TOBEC, Hashimoto et al 2002), and dual energy X-ray
absorptiometry (DEXA, Schmelzle and Fusch 2002).
One theory suggests that the number of cells in an organism, rather than its
weight, is the determinant of its metabolic rate (Cheek 1968, Shelton 1980). Thus an
underweight child with a normal cell number for age would have a "high" metabolic rate
in relation to weight in comparison to a normally nourished child of the same age.
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Some workers feel that nutritional requirements and metabolism relate more
closely to surface area (Butler and Richie 1960).
1.2.6 Hypothesis and study objectives
The hypothesis was that infants with CHD show poor body growth because of an
abnormality in the partitioning of energy balance, hence leaving less energy available for
deposition.
The main objective was to measure growth and the components of energy balance
in infants with CHD and controls. In order to carry this out, two intermediate objectives
had to be achieved:
(a) To adapt and validate available methods of investigating energy balance for
studying the partition of daily energy balance in infants.
(b) To measure respiratory gas exchange over prolonged periods in infants using
indirect calorimetric methodology, and hence derive resting energy expenditure.
The approach was to carry out a descriptive study of hospitalized infants with
congenital heart disease and to compare them with controls. No formal estimation of
sample size was performed.
1.3 NUTRITION AND GROWTH IN BRONCHOPULMONARY DYSPLASIA
1.3.1 Definition and pathogenesis of bronchopulmonary dysplasia
Bronchopulmonary dysplasia (BPD) or chronic lung disease in preterm infants
has been a significant problem because of the improved survival of the most preterm
infants related to better cardio-respiratory intensive care. It is a cause of prolonged
hospitalization, and these infants have a higher mortality and long-term morbidity (Eber
and Zach 2001). In the years since the current work was carried out, the pattern of
neonatal chronic lung disease has altered, probably because of improvements in obstetric
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care and early neonatal respiratory care, so that it is now predominantly a condition seen
in babies born below 28 weeks gestation or 1kg birthweight (Bancalari et al 2003).
It is very likely to be multifactorial in causation, and numerous factors have been
implicated. The quality of early nutrition in preterm infants may have a bearing on many
of these factors and may thus affect respiratory outcome.
(a) Structural and biochemical lung immaturity. Low gestational age and
birthweight are the strongest risk factors for BPD. This may reflect the effects of
ventilation on anatomically underdeveloped lungs with poorer antioxidant defences, but
may also reflect the greater likelihood of smaller babies encountering the other risk
factors.
(b) Mechanical trauma from ventilation. Most babies with chronic lung disease
have required artificial ventilation for early lung disease. Although there is little evidence
from prospective controlled trials that a particular aspect of artificial ventilation is
critical, it is generally accepted that positive pressure is contributory (Taghizadeh and
Reynolds 1976, Attar and Donn 2002).
(c) Oxygen toxicity The occurrence of BPD has been related to the duration of
exposure to high concentrations of inspired oxygen (Edwards et al 1977). Exposure of
experimental animals to 100% oxygen results in lung changes similar to BPD (Winter
and Smith 1972). Antioxidant enzyme systems are probably immature and other
antioxidant factors may be deficient in preterm infants, particularly those that develop
BPD (Frank and Sosenko 1987).
(d) Infection. Respiratory colonization with organisms that are normally of low
virulence is typical of preterm babies who are ventilated. These organisms may set up
low-grade inflammation contributing to lung damage. Ureaplasma and mycoplasma have
been implicated in the causation of preterm delivery and neonatal lung disease, although
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the evidence for an aetiological role is conflicting (van Waarde et al 1997). The
concurrence of systemic infection and a persistent ductus arteriosus significantly increase
the risk of BPD, and this may be because infection results in the release of mediators
which delay the closure of the ductus (Gonzales et al 1996).
(e) Inflammation This is part of the pathological process in the respiratory disease
of preterm infants. There is cellular and humoral evidence of active inflammation in
neonates with chronic lung disease (Pierce and Bancalari 1995).
(f) Increased interstitial fluid in the lungs. High fluid intakes and the presence of
a patent ductus arteriosus have been associated with an increased risk of developing BPD,
possibly because of their common effect on increasing interstitial fluid in the lungs
(Tammela 1995).
(g) Recurrent milk aspiration. The predisposition of preterm infants with
respiratory difficulty to gastro-oesophageal reflux, and the detection of fat-laden
macrophages in the bronchoalveolar fluid suggests that this might be important in at least
some infants (Radford et al 1995).
(h) Deficiency of micronutrients Deficiency of vitamin A may lead to poor
epithelial healing. Pathological changes in the lungs are very similar to those of BPD
(Zachman 1985). Inositol, a phospholipid which is thought to enhance the synthesis of
surfactant in the lungs, may be functionally deficient in preterm infants (Howlett and
Ohlsson 2000).
Past studies of chronic lung disease are confounded, even in just quoting
incidence, by differences in definition. The original definition of bronchopulmonary
dysplasia was: "The continued requirement for added oxygen at 28 days postnatal age in
a baby who initially required ventilation for lung disease, and who has radiological
changes compatible with BPD". Each of the components of this definition has been
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modified by different workers. This definition may no longer be very useful for clinical
and research purposes, particularly since the most premature infants can be expected to
require respiratory support for longer in relation to lung immaturity and poor respiratory
drive. A modified definition taking account of the corrected age of the infant may be
more appropriate (Shennan et al 1988), although this approach may exclude babies with a
significant clinical problem, and has been questioned again recently (Bancalari et al
2003).
1.3.2 Undernutrition in the causation of BPD
A deficiency of macro- and micronutrients may play an important role in the
pathogenesis of bronchopulmonary dysplasia, although it is only recently that an attempt
has been made to study this (Frank and Sosenko 1988). Undernutrition may predispose
the baby to the harmful effects of many of the other insults implicated in causation. The
rationale of suggesting a pathophysiological link between BPD and undernutrition can be
understood by considering the situation commonly confronted by a very low birth weight
infant. The baby of 1kg has a non-protein caloric reserve of only about 1 lOkcal/kg (520
kJ/kg), which is barely sufficient for a day's total energy requirements. Respiratory
disease is likely to increase energy demands by up to 25% (Weinstein and Oh 1981), and
the pain and stress related to intensive care pose a further catabolic threat (Rogers 1992).
Undernutrition might potentiate oxidative injury, and impair protective responses against
infection (Farthing and Keusch 1985). Inadequate rib mineralization and intercostal
muscle strength may lead to inefficiency of chest wall movement (Glasgow and Thomas
1977), and thus prolong the need for potentially damaging ventilatory support.
It is interesting that preterm infants who are also small for gestational age, although
having a reduced likelihood of early neonatal lung disease, are more likely to develop
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chronic lung disease. This may partly be the result of restriction of lung growth in ntero,
and also because of a deficiency of lung-protecting nutrients (Lai et al 2003).
(i) Macronutrients
Deficiency of macronutrients (protein and energy) may lead to an inability to grow
and repair immature, damaged lung tissues. In experimental newborn animals, moderate
undernutrition results in severely restricted lung growth, and markedly increases the
mortality related to hyperoxia (Frank and Groseclose 1982). There is some evidence that
gross undernutrition precedes the development of BPD in very low birth weight babies
(Wilson et al 1991). However, the same author did not show a reduction in the incidence
of BPD in this population with a package of measures resulting in an increase in
nutritional intake (Wilson et al 1997).
(ii) Micronutrients
Micronutrients important for the protection of the lung from damage and for lung
growth and repair may also be deficient.
(a) Anti-oxidant defences. Vitamin E is an important natural antioxidant, and
is difficult to supply in quantities approaching those accreted transplacentally in the 3rd
trimester of pregnancy, particularly if enteral nutrition has to be delayed (Gutcher et al
1984). The ratio of vitamin to polyunsaturated fatty acids (PUFAs) in the diet seems
crucial in protection against oxygen toxicity (Witting 1980). Vitamin E is probably
provided in sufficient amounts in infants fed milk. However, parenteral nutrition
solutions may have low levels of biologically active vitamin E in the presence of large
quantities of PUFAs (Gutcher et al 1984). Supplementation with pharmacological doses
of vitamin E has not been shown to improve respiratory outcome (Watts et al 1991), and
may predispose to necrotising enterocolitis and sepsis (Johnson et al 1985).
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Copper, zinc, selenium and manganese are essential components of the
antioxidant enzymes superoxide dismutase and glutathione peroxidase, which are present
in low levels in preterm infants (Walravens 1980, Forman et al 1983). Serious deficiency
of these trace elements is unlikely to occur unless infants are fed parenterally for a
prolonged period.
The sulphur-containing amino-acids cysteine and methionine also have important
anti-oxidant properties, probably because they bind oxygen free radicals and their
deficiency has been shown to increase mortality resulting from hyperoxia in rats (Forman
et al 1983).
(b) Vitamin A. Vitamin A is involved in the regulation of growth and
differentiation of many tissues, and maintains the integrity of epithelial cells. It may also
have a role in immune function. Vitamin A stores are low in preterm infants (Shenai et al
1981), and stay especially low in infants who develop BPD (Shenai et al 1985). It is
difficult to deliver sufficient vitamin A postnatally, especially by the parenteral route,
because of light degradation and adherence to the tubing of giving sets during
administration of parenteral nutrition (Green et al 1987). Intervention studies have shown
conflicting results, and this may be because of differences in patient populations, and in
the route and dosage of supplementation. In a recent meta-analysis, the conclusion was
that vitamin A supplementation (given enterally or intramuscularly) resulted in a modest
reduction in the combined outcome of death or oxygen requirement at one month of age
in babies of birthweight <1500g, and in a reduction in need for supplemental oxygen at
36 weeks postconceptional age in babies of birthweight <1000g (Darlow and Graham
2002).
(c) Inositol A single large randomized double blind study (Hallman et al 1992)
supplementing preterm infants receiving parenteral nutrition in the first five days of life
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showed an increased survival without requirement for supplemental oxygen at 28 days. A
meta-analysis suggests an additional reduction in grade 3 or 4 intraventricular
haemorrhage and in significant retinopathy of prematurity (Howlett and Ohlssen 2000).
1.3.3 Feeding practice and the causation of BPD
Whilst adequacy of nutrition has been recognised as of theoretical importance for
babies with chronic lung disease, various aspects of enteral and parenteral feeding have
been under suspicion in exacerbating respiratory disease, the resulting caution creating a
further threat to the nutritional status of these infants. Concerns about the possible
deleterious effects of enteral feeding on respiratory disease as well as the risk of
necrotising enterocolitis have led to the practice of delaying milk feeding. Recurrent
silent aspiration of intragastric milk feeds has been proposed as an aetiological factor in
chronic lung disease, although gastro-oesophageal reflux appears to be no more (and
perhaps even less) likely in ventilated infants (Newell et al 1989). Evidence linking the
speed of introduction of enteral feeds with necrotizing enterocolitis is, at best, equivocal.
Some studies suggest that the likelihood of necrotizing enterocolitis may even be reduced
by early enteral feeding (LaGamma 1985). The better enteral tolerance of expressed
breast milk and the protection it provides against necrotising enterocolitis (Lucas and
Cole 1990) have further reduced any rationale to delay enteral feeding for a prolonged
period.
Complications related to the use of older formulations and the previously less
controlled administration of parenteral nutrition solutions have led to great caution in
their use. The pulmonary complications of parenteral lipid emulsions (Hammerman and
Aramburo 1988) are probably avoided if dosage is regulated, and blood monitored for
lipaemia (Spear et al 1986). Parenteral lipid preparations provide an important source of
energy, without some of the side effects of intravenous dextrose. Dextrose when given
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alone has been shown to increase metabolic rate and carbon dioxide production because it
is converted to lipid, a process which is energy-requiring and has a high respiratory
quotient (VanAerde et al 1986). Intravenous lipid is also an important source of essential
polyunsaturated fatty acids, which may themselves have an antioxidant role (Sosenko et
al 1988). On the other hand, total parenteral nutrition cannot easily provide the preterm
infant's requirements of vitamin A (photodegradation, Gillis et al 1983) and vitamin E,
calcium and phosphate (limitations of solubility: Shine and Farwell 1984) and some of
the trace elements.
The conflicting concerns in sick infants about, on the one hand adequacy of
nutrition, and on the other the possible side effects of feeding have resulted in a lack of
consensus about this important aspect of neonatal intensive care, and there have been
widely varying policies among units (Churella et al, 1985).
1.3.4 Growth in BPD
Good growth is an important aim in itself, but also reflects adequacy of nutrition
in chronic disease. Several studies have looked at long-term growth in infants with
chronic lung disease. Markestad and Fitzhardinge (1981) looked at growth in 20 babies
with BPD, without comparison with a control group. They found that all infants were at
or below the 3rd centile for weight and length at term. Over the next two years, although
some catch-up growth occurred, expected size had not been achieved in anything but
head circumference. Acceleration in linear growth usually coincided with a marked
improvement in clinical respiratory status. Meisels et al (1986) studied 17 babies with
BPD with preterm controls matched for birthweight and gestation, and found twice as
many BPD babies as controls to be less than the 10th centile for weight and length in the
2nd year (although this was not statistically significant). Davidson et al (1990) compared
30 infants with BPD with 41 preterm controls, although it was found difficult to match
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for birthweight and gestation. They found lower weight and height centiles in female
BPD infants throughout the first 2 years of life, although in the group as a whole, the
difference was only significant at the final assessment at 21 months. Vohr et al (1982), in
a controlled study did not find any difference in growth during the first 3 years in BPD
and control infants.
Growth retardation in these babies may occur partly because they are the most
preterm, and the sickest babies, under the greatest nutritional stress during their acute
illness. Even when stable, these babies are as a whole restricted in their fluid (and hence
nutrient) intake because ofworries about worsening interstitial lung fluid, or precipitating
cardiac failure. They may not feed well orally because of dyspnoea and other coexistent
complications of prematurity.
Dexamethasone has been used extensively for the treatment of lung disease in
neonates. It has been found to help wean such infants off the ventilator (Avery et al
1985), and there is a suggestion that it might be helpful early in the course of lung disease
in preterm infants. Dexamethasone treatment is associated with an acute slowing of
growth (Skinner et al 1997).
There has been a suggestion that chronic or recurrent low grade hypoxaemia may
contribute to growth failure in BPD (Moyer-Mileur et al 1996).
It is not clear what part is played by "emotional" stunting because of abnormal
environment and the recurrent stresses these babies endure for long periods.
Recent work suggests the importance of inflammatory mediators in modulating
nutritional status in adult chronic obstructive pulmonary disease and cystic fibrosis (Bell
et al 2000). There is certainly evidence that bronchopulmonary dysplasia is associated
with a persistent inflammatory response (Groneck and Speer 1995), and this may
contribute to cachectic changes in BPD, although this has not been studied.
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1.3.5 Energy balance in BPD
Energy is an important component of nutrition in preterm infants. Because a large
proportion of energy intake is used for growth (up to 50%, Reichman et al 1982),
energy is likely to be a limiting factor for growth.
There is some evidence that bronchopulmonary dysplasia is associated with
hypermetabolism as assessed by indirect calorimetric measurements of respiratory gas
exchange (Yeh et al 1989, Weinstein and Oh 1981, Kurzner et al 1988a). This may partly
be the result of the increased work of breathing (Kurzner et al 1988b), and possibly
cardiac work especially if there is coexistent pulmonary hypertension, and may result in a
reduction in the amount of energy available for deposition. There has been some criticism
about the methodology and interpretation of the studies of metabolic rate (Kalhan and
Denne 1990). Measurement of oxygen uptake by indirect calorimetry relies on measuring
small differences in oxygen concentration between inspired and mixed-expired gases. In
babies receiving supplemental oxygen, small and undetected variations in inspired
oxygen concentration will have a large effect on measured oxygen uptake. None of these
studies included any validation of the methodology specifically for oxygen-dependent
subjects.
Energy intake was found to be reduced in infants with BPD early in their life
(mean 60 days postnatal age, Yeh et al 1989), but not later (6 months corrected age,
Kurzner et al 1987). Both these studies showed no difference in energy absorption from
the diet. The study of Yeh et al (1989), in addition, indicated a low energy cost of growth
in BPD, suggesting an altered composition of tissue gain.
Dietary caloric supplementation with glucose polymers (Yunis and Oh 1989), and
theophyllines used to improve pulmonary function (Gerhart et al 1979) may increase
energy expenditure for the same reason as intravenous glucose. Steroids used to wean
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babies with BPD off ventilatory support cause catabolism, with a likely increase in
muscle protein breakdown (Brownlee et al 1992).
1.3.6 Bone mineralization in bronchopulmonary dysplasia
There is very rapid accretion of bone mineral during the last trimester of
pregnancy. Poor bone mineralization (metabolic bone disease or osteopenia of
prematurity) is seen commonly in very low birth weight infants (Ryan 1998). It is thought
to be mainly due to a postnatal shortfall of mineral intake, and there have been reports of
achievement of intrauterine rates of mineralization with supplemented feeds (Chan et al
1988). The shortage of mineral supply may be made worse by the therapeutic use of
diuretics and steroids used to produce short-term improvement in pulmonary function in
infants with chronic lung disease (Shrivastava et al 2000). This may contribute to the
retarded linear growth seen in preterm infants, although if their smaller body size is taken
into account bone mineral content has caught up by the age of 1 year (Congdon et al
1990). In theory, poor mineralization of the ribs might play a part, during the neonatal
period, in perpetuating chronic respiratory disease by causing atelectasis due to inefficient
splinting of the chest wall (Glasgow and Thomas 1977).
Greer and McCormick (1987) compared VLBW infants with and without BPD
matched carefully for gestation and birthweight, and did not find that bone mineralization
was affected by the presence of BPD. They did not specifically look at the effect of drug
therapy. Adrenal corticosteroids may, in addition to their effect on bone mineral, retard
bone growth by suppressing collagen synthesis, and by slowing the function of the bone
growth plate, perhaps by reducing pituitary growth hormone secretion or the production
of local growth factors (Preece 1976).
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1.3.7 Hypothesis and study objectives
The hypothesis was that evidence of impaired nutritional status precedes (and
might contribute to) the development of chronic lung disease, this deficit persisting once
BPD is established, and being associated with poor body growth.
The objectives were to:
(a) Measure growth and macronutrient intake in the first few weeks of life in babies who
go on to get BPD and in controls
(b) Measure energy balance in infants with established BPD and controls
(c) Measure forearm bone mineral content longitudinally from birth in babies with BPD
and controls.
The approach was to carry out descriptive studies of nutrition in infants with BPD
and compare them to control preterm infants without BPD. No formal estimation of
sample size was performed for these studies.
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Chapter 2 Methods
2.1 CONGENITAL HEART DISEASE For Results, see 3.1
For Discussion, see 4.1
These studies were carried out over the 2 years 1981-1983. An initial period was
spent in development and validation ofmethodology. Studies of energy balance and
growth were then carried out on inpatients recruited from the cardiology and general
paediatric wards in the Royal Liverpool Children's Hospital. This hospital provided a
tertiary referral service for paediatric cardiology and cardiothoracic surgery for
Merseyside and North Wales.
Energy balance studies were carried out on infants with and without CHD. For
ease of description, the studies are considered in 3 parts:
(1) Measurement of Energy Intake and Losses (in stool, urine, and vomitus),
(2) Measurement of Energy Expenditure or Metabolic Rate,
(3) Measurement ofGrowth.
2.1.1 Ethical approval and Consent
The study was approved by the Liverpool Paediatric Sector Ethical Committee.
Parents or guardians were fully informed about the study, and written consent was
obtained.
2.1.2 Study design
For this explanatory study, a convenience sample of hospitalized infants with
CHD and healthy infants of a similar age range was enrolled and the groups compared
from the point of view of nutritional status.
2.1.3 Selection of cases
Stable hospitalized infants with CHD but without any major associated
abnormality were eligible for the study. The requirements of the energy balance study
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were such that infants needed to have limited independent mobility and still be dependent
on napkins (for the measurement of intake and losses), and able to be nursed in a
metabolic chamber for several hours (energy expenditure). They were thus usually below
the age of 6 months post-term age. Controls were healthy infants on the general paediatric
wards, admitted or kept in hospital following an acute illness for predominantly non¬
medical reasons.
2.1.4 Energy Intake and Losses
Infants were nursed in a hospital cot on a ward in the Royal Liverpool Children's
Hospital. They were studied over a period of 3-5 days when their clinical condition was
judged to be stable. Their feeding regimen and treatment were not changed, and they
were not subjected to major procedures such as cardiac catheterization during the study
period. They were examined daily, and the following recorded: (a) sleeping heart rate, (b)
sleeping respiratory rate, (c) presence or absence of central cyanosis, (d) liver size, (e)
peripheral oedema. Blood samples were taken at least on alternate days for (i)
haematocrit, (ii) urea and electrolytes, (iii) capillary blood gases.
(i) Energy Intake
Infants were included in this part of the study only if their diet consisted solely of
commercial formula milk. Most infants were fed pre-packed commercial formula milk.
Two infants were fed formula milk made from powder in the hospital milk kitchen. In the
latter cases, a whole day's supply was reconstituted, and the required number of bottles
fdled from this supply and sealed in the milk kitchen. The feeding regimen for each
infant was decided upon by the medical and nursing staff responsible for the care of that
infant, well before the start of the study, as that most appropriate to his/her clinical
condition. Individually numbered milk bottles were weighed before and after feeds
(Mettler top pan balance).
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Samples of each type of pre-packed formula, and samples of each batch of locally
prepared milk were analysed for energy content. lOOg aliquots (measured on a Mettler
top-pan balance) were frozen in round-bottom flasks. The weight of dry residue was
measured and its heat of combustion determined by bomb calorimetry on at least 10
occasions. The mean was taken from readings showing a standard error of less than 3%,
and hence the energy content of the milk calculated (Miller and Payne 1959).
(ii) Energy Losses
(1) Collections Infants wore closely fitting disposable napkins (Boots,
disposable) with porous napkin-liners (Boots, 5-star), the whole being held onto the
infant with a plastic napkin-tie. This system provided some separation of stools (retained
by the napkin-liner) from urine (soaked into the napkin).
Infants were nursed on large absorbent bibs (Molynlycke, Sweden) to collect milk
spillages and vomitus.
Napkins and bibs were changed as soon as they were seen to be soiled, and stored
in individual sealed "freezer bags" in a freezer at -20°C.
Extra napkin-liners and bibs were used, as appropriate, to clean the infant's skin
when changing.
Topical applications to the napkin area were avoided during the study.
50mg of Carmine powder (sterilized by the local pharmaceutical quality control
lab. to avoid contamination, Lang et al 1967) was mixed with the first feed of the balance
period, and the first feed after its completion (see Fig. 2.1). This marker has a gut transit
time similar to food, and appears unchanged in the stool (Rose 1964). Stool collections
were started with the first appearance of the first marker, and stopped with the first
appearance of the second marker.
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Day no. 1 2 3 4








vomit collection< - >
Fig. 2.1 Diagrammatic Representation of 3 day study of energy intake and losses.
Nurses instructed in the procedures involved were responsible for most of the
day-to-day care of infants, involving feeding and changing. They also recorded the bottle
numbers used at each feed, and the length of time taken over feeding. They stored bottles,
containing any unfinished milk, as well as used napkins, bibs and liners, individually
wrapped, in a freezer used specifically for this purpose and kept by the infant's cot. The
nurses were supervised daily, and practice-runs exposed possible technical problems, and
improved techniques. Napkins were checked to fit closely to the infant; any loose folds
were gathered together with surgical tape. Infants were nursed and fed always with bibs
strategically placed to catch vomits. Initially, major accidental losses were common but
with time, these became less frequent. Any such major losses were reported, and resulted
in that study being abandoned or restarted.
(2) Processing (a) Urine and vomitus For ease of handling, urine and vomitus
were dealt with together (see p49-50).
Napkins and bibs were weighed individually and labelled before use. A
day's collection of used napkins and bibs was thawed from the freezer and re-weighed
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individually. Thus the weight of urine and vomitus collected each day was calculated.
After weighing, napkins and bibs were thoroughly shredded by hand, in a plastic basin,
with 1 to 3 litres of tap water. The resulting pulp was filtered in portions through a 500ml
Buchner funnel using Whatman filter paper into a 51 flask connected to the laboratory
wall suction unit. Measured volumes of water were used to wash each funnel-full, and
filtered for a measured time, after which residual water was forced out using a large
weight on the pulp.
Four 250ml aliquots of the thoroughly mixed filtrate (measured with a graduated
measuring cylinder) were frozen at -20°C for 48 hours in Pyrex-glass round-bottom flasks
of known weight. The frozen samples were freeze-dried (Edwards Modulyo freeze-drier,
Edwards High Vacuum, UK) to obtain a small residue whose weight was determined by
weighing the re-warmed flask.
The energy content of the residue was determined by bomb calorimetry in
triplicate. Daily energy loss was calculated from the known amounts of urine and vomitus
collected and the known dilution (for details, see p49-50).
(b) Stool The average weight of napkin-liners was determined by
weighing a large number together.
A day's collection of liners was thawed and then weighed collectively, to
determine the amount of stool collected. Stool was carefully scraped off liners with a
metal spatula, into a pre-weighed plastic container representing a day's collection. This
was weighed to determine the amount of stool processed. The stool was freeze-dried in
these containers, which were weighed after warming to determine the weight of residue.
The residue was homogenised and its energy content determined by bomb
calorimetry in triplicate.
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Assuming the daily stool collection to be homogeneous in energy content, daily
energy loss in stool was then calculated:
Energy content of residue x wt. of stool collected /wt. of stool
processed
Daily energy loss in stool =
-<
(c) Quality Control
(i) Collection of losses Experiments were carried out to determine
the optimum method of processing napkins and bibs.
Experiment 1. To determine the method providing the best energy yield A 1:5 volume
dilution of pre-packed milk was prepared. Aliquots of this were freeze-dried for bomb
calorimetry to determine energy content. Further aliquots were poured onto batches of
pre-weighed napkins and bibs, which were then re-weighed to determine the amounts of
milk added. 6 napkins and 3 bibs were used in each batch as the average number used per
day on infants during the study. The soiled napkins and bibs were shredded with added
water in a basin (the plastic backing was taken off bibs and cleaned of possible residue
with water) until they were, subjectively, of a workable consistency. Different batches
were then treated in different ways: (a) varying the number of extra washings to each
Buchner funnel full of pulp, (b) varying the length of each filtration.
The energy content of the filtrate was determined by bomb calorimetry. Assuming
that the filtrate was a homogeneous mixture of 1:5 diluted milk and the water added, the
energy content of the original 1:5 diluted milk could be extrapolated, and compared with
the value obtained by direct measurement.
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Energy in 1:5 diluted milk (kJ/lOOg)


















There was no clear trend in energy obtained with increasing washings, with a
coefficient of variation of 3.2%. There was a mean deficit of 11.8% (range 7.8-15.4%) in
energy obtained. Two washings were decided upon.
With one batch of milk-soiled napkins and bibs, portions were subjected to
washings of different duration.
2 washings- duration of Total energy in 1/5 milk
each washing (min) derived from filtrate (kJ)
There appeared to be no significant benefit to washings of longer than 2 minutes
duration, and this is what was used in the study.
Experiment 2. To ensure the lack of energy contribution from experimental materials
Batches of unused napkins, bibs and filter-papers were homogenised, in turn, in water
and processed as above. No visible residue was obtained after freeze-drying the filtrate,
and there was no consistent weight rise of the flasks.
Milk of known energy content was added to these flasks and freeze-dried after












(ii) Bomb calorimetry Bomb calorimetry was carried out using
conventional techniques (Miller and Payne, 1959) using a ballistic bomb calorimeter
(Gallenkamp, UK).
Sufficient familiarization with the instrument to obtain reproducible results
requires much time and attention to detail; hence the exact technique used here will be
described.
The instrument measures the heat of combustion of materials. The material to be
tested is placed, suitably prepared, in a crucible inside the sealed bomb calorimeter
chamber, and oxygen introduced at 25 atmospheres pressure. The substance is ignited by
the burning of a standardized cotton fuse attached to an electronically heated coil,
operated by a switch. A thermocouple converts the heat transmitted to the calorimeter
casing into an electrical signal displayed on a galvanometer previously calibrated using a
standard.
In the present study, a standardized length of single thickness cotton (supplied
with the bomb calorimeter) was used as the fuse. Burning the fuse on its own produced a
small galvanometer deflection, whose value was derived after burning several of these
together. This "fuse deflection" was subtracted from all subsequent measurements.
A single metal crucible was used throughout, since it was found that there was a
greater discrepancy between measurements using different crucibles.
The mode of preparation of the sample, leading to optimal combustion, varied for
different materials. Optimal combustion was reflected, in practice, by: (i) a smooth rise in
chamber pressure after ignition, (ii) no visible unburnt material left in the crucible, (iii)
no "spraying" ofmaterial outside the crucible, (iv) reproducible results.
Benzoic acid, used as a standard, was melted in a crucible over a Bunsen burner
flame - this converted it from a fine powder into a compacted layer in the crucible. The
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crucible was weighed empty and after the melted benzoic acid had cooled to room
temperature, before combustion. Other materials were prepared as a dry powder by
freeze-drying, homogenized, and then packed tightly into the crucible.
The time-course of galvanometer deflection after ignition was studied using
different materials. In all cases the deflection reached a definite peak after between 30
and 40 seconds. In many cases a second peak was obtained after about 3 minutes, but this
was much less constant. The first peak showed a linear dose-response of sample size to
size of deflection intersecting the origin. For the purposes of calculation, the first peak
deflection read naked eye on the galvanometer dial was used.
The bomb calorimeter was calibrated daily to allow for the influence of
environmental changes. Benzoic acid conforming to a thermochemical standard (Bureau
ofAnalysed Samples Ltd., UK, 26.44 kJ/g) was used. Three successive calibration values
showing a standard error of the mean of less than 3% were averaged and a value for
kJ/unit deflection calculated (if a wider error was obtained the instrument was checked




Respiratory gas exchange was measured to provide an indirect estimate of energy
expenditure. Attempts were made to develop a system with which infants could be
studied over a period of several hours, in different states of activity, without sedation, and
with minimal restriction on their normal activity.
Fig. 2.2. Diagram of metabolic chamber
oxygen analyser carbon dioxide analyser
Fig. 2.3. Diagram of circuit for measuring gas exchange
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The infant was nursed in a perspex whole-body chamber (see Fig. 2.2), through
which room air was drawn by a standard wall-fixed suction apparatus on the ward. A
plastic funnel at the "expired" end of the chamber served to mix the expired gases, which
were dried by passing through a tube of calcium chloride granules (B.D.H., UK).
The flow rate of mixed expired air was continuously measured using a Hastings
linear mass flowmeter (ENALL 10K, Teledyne Hastings-Raydist, USA). Oxygen
concentration was measured with a paramagnetic oxygen analyser (OA 272, Taylor-
Servomex, UK); carbon dioxide concentration with an infrared analyser (P.K.Morgan
80ID, UK) (Fig 2.3). During a study, the gas analysers were intermittently switched to
sampling room air (every 30 minutes).
The infant's skin and rectal temperatures, and chamber air temperature were
measured by thermistor probes (Yellow Springs Instruments, series 400), attached to an
electronic switch-box (YSI model 47).
Flow rates, gas concentrations, and temperatures were recorded on a calibrated,
multi-channel chart recorder (Chessels model 302, UK).
Before starting measurements, the flowmeter was electronically zeroed, and the
gas analysers calibrated within a narrow scale using two different standardized gases
(BOC Certified gases).
The chamber containing the infant was closed and the suction started. A flow rate
was used which resulted in a 'A-1% difference between inspired and expired gas
concentrations.
Each infant was studied over several hours, with frequent records of changes in
the state of wakefulness or activity. When necessary, the infant could be quietened or
attended to through portholes in the side of the chamber, with little interruption in the
measurements.
53
Using a planimeter (Haff model 315, Gebruder Haff GmbH, W.Germany) to
measure areas under curves, averaged inspired-expired concentration differences and
flow rates were calculated for short periods (usually 10 minutes).
Energy expenditure was calculated from V02 using the equivalence tables of Zuntz
(Harper et al 1979) using the total RQ and ignoring the contribution of protein to
metabolism.
For the purposes of comparison between infants, sleeping oxygen uptake and
respiratory quotient, and an estimate of resting energy expenditure (REE) derived from at
least 3 hours of resting measurement are used here.
In those who had a complete balance study, energy available for deposition in new
tissue was estimated by subtracting REE from metabolizable energy intake,
(ii) Development ofmethodology
An open-circuit indirect calorimetric method with a whole body chamber was
used in this study.
Such a method needs to fulfil several basic criteria:
(i) A comfortable subject in a "thermoneutral" environment,
(ii) A rate of airflow through the chamber which avoids stagnation of expired
gases and re-breathing of carbon dioxide,
(iii) A net unidirectional flow of air through the circuit with complete entrainment
and thorough mixing of expired gases, and no outward leaks,





Flow rate of dry mixed expired air (corr. to STP)
X
Average inspired-expired conc. difference
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(v) Validity of the system as a whole for measuring gas exchange.
The equipment used will now be described in some detail and the above points
discussed.
(1) The Chamber
A headbox with a sleeve over the infant's body was tried initially, but this was too
restricting in all but the youngest infants, and caused major problems with condensation.
It also resulted in a poorly damped trace which showed large minute-by-minute changes
in gas exchange.
A prototype whole-body chamber consisted of a perspex box of shoe-box shape.
One end wall was moveable, so that the length of the chamber could be adjusted. There
was one small entry port and similar exit port for gases at opposite ends. Several
modifications subsequently improved the function of the chamber.
The eventual size of the chamber was such as to allow relatively free movement
of the largest infant studied, whilst not being so large that it created an unwieldy dead
space, slowing the response time of the system. For comfort, the infant lay on a foam
mattress 7 cm thick covered with a single sheet.
The pattern of gas flow through the chamber was studied (a) using a smoke
generator, (b) by measuring oxygen and carbon dioxide concentrations inside the
chamber whilst an infant was being studied. Smoke (which, like carbon dioxide, is denser
than air) tended to collect at the base of the chamber. This tendency was lessened by (i)
making multiple perforations in the end walls and attaching plastic funnels to each end,
(ii) placing obstacles to divert gas flow on the floor of the chamber, thus creating
turbulence (the infant may have served this function during studies). The funnel at the
exit end, also served to mix expired gases by creating turbulence.
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During a gas exchange study, the carbon dioxide concentration was somewhat
higher near the base of the chamber. However, the maximum concentration difference
between two points was 0.2% and the highest C02 concentration was 0.8%.
Two portholes were created on one side of the chamber -to these were attached
tightly fitting elasticated sleeves which could be sealed when not in use. These allowed
access during a study, for calming a distressed infant, and for nappy-changing or even
feeding. A quick-access hatch was provided on top of the chamber for emergency use.
(1) Flowmeter Hastings linear mass flowmeter, model ENALL 10K (Teledyne
Hastings Raydist, USA). This instrument measures gas flow to 0.01 litres/min between 0
and 10 litres/min, and is calibrated for air.
Its calibration was checked with an Ealing dry gas meter (Scientific and Research
instruments, UK), which measures gas volumes with an accuracy of +/-1%. Using room
air, and measuring gas volume at a constant flow rate for 10 minutes, the two methods
showed a linear correlation in the range 0-10 litres/min.
There was some electrical baseline drift in the first 15 minutes after connecting to
mains, but thereafter minimal drift of +/-0.02 litres/min over 18 hours whether connected
to gas flow or not.
During gas exchange studies, the flowmeter was measuring dried mixed-expired
air, with a higher carbon dioxide and lower oxygen content than room air. When such
changes in concentration (up to 1%) were artificially induced by introducing standard
gases, there was no measurable effect on the calibration of the flowmeter.
(3) Oxygen analyser Servomex OA272 paramagnetic oxygen analyser
(Taylor Servomex, UK). This was used with a pump diverting 100ml of dried mixed-
expired air into the analyser. The analyser can measure oxygen concentrations between 0
and 100% and has the facility of using an enlarged scale to look at a 25% or 5% oxygen
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full scale, anywhere in the range of 0-100% oxygen. In the present studies, a scale of 5%
in the range 20-25% oxygen was used, the upper and lower limits of the scale being
calibrated using standardized gases (BOC certified gases, British Oxygen Co., UK). (The
upper and lower limits can be set separately, and the whole scale can be moved using a
"shift" control).
Calibration drift was assessed with the analyser sampling room air over a period
of 18 hours. There was some drift in reading around the baseline, which was related to
shift in the whole 5% scale rather than an alteration in the upper or lower limit
calibration. Drift over 1 hour was up to 0.05%, and during a study this was corrected
using the shift control every 30 minutes, after noting on the trace the amount of drift.
(4) Carbon dioxide analyser PKMorgan model 80ID (PK Morgan, UK)
infrared carbon dioxide analyser. This measures carbon dioxide concentrations between
0 and 5%. It has an inbuilt pump, which withdraws 2 litres of dried mixed-expired air.
Room air drawn through self-indicating soda lime was used as a zero, and a BOC
certified calibration gas with about 2% carbon dioxide for a "high" calibration.
After a 1 hour warm-up period, there was little drift over 18 hours (up to 0.01%
C02) and negligible drift over 30 minutes in zero and 2% calibrations, provided the soda
lime in the instrument was renewed regularly (every 4 hours).
(5) Thermal monitoring and thermal stress Yellow Springs Instruments
(USA) YSI series 400 thermistor probes; YSI model 47 multi-channel temperature
monitor. The air temperature probe was fixed at the expiratory end of the chamber; the
skin probe stuck to the skin of a finger or toe with adhesive tape; the rectal probe was
used in most cases to obtain intermittent readings. The monitor switched to each of the
channels in turn.
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It was decided to study infants in thermal conditions as near to those in which
they would normally be nursed as possible. Infants were studied lightly clothed with a
napkin and a single thin layer of clothing over the trunk at room temperature which was
18 to 22°C. The chamber air temperature did not vary more than 0.5°C from the
temperature on the ward. Infants' body temperatures did not vary by more than 0.5°C
from 36.5°C (skin) and 37°C (rectal), and the peripheral-core temperature gap was never
greater than 0.5°C, suggesting that infants were not under thermal stress.
(6) Chart Recorder Chessels, model 301, 6-channel chart recorder (Chessell
Ltd, UK). To this was connected the millivolt output of the oxygen and carbon dioxide
analysers, flowmeter and thermistor switch box. The recorder was set up so that the full
scale represented roughly 1% change in gas concentration and 0.5 litre/min flow rate.
(7) Entrainment of expired gases
No attempt was made to make the chamber completely airtight, as small leaks
would be into the chamber, and this would not affect the gas exchange calculations which
are based on "expired flow" being measured. However, the more distal part of the circuit
needed to be airtight to ensure a complete yield of expiratory gases.
With a constant flow of room air entrained through the chamber, a standardized
gas was introduced into the chamber at a constant rate measured by a rotameter (up to
lOOml/min) to produce O2 and CO2 concentration changes of around 0.5% as in an infant
study.
O2 and CO2 production (from the cylinder), determined from the measured gas
concentrations and flow rate of "mixed expired" gas, were compared with the values
calculated from the known composition and flow rate of the cylinder gas. The mean error
from calibrations was 4.3% (range 0.5-5.9%).
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Flow of 100% C02 Flow of "mixed Measured C02 Measured C02 0//O
(ml/min) expired" gas cone, in mixed production Error
(I/min) exp. gas (%) (ml/min)
10 2 0.47 9.47 -5.3
20 4 0.52 20.94 +4.7
30 6 0.53 31.77 +5.9
40 8 0.48 38.42 -3.95
50 10 0.53 52.75 +5.5
60 6 0.94 56.52 -5.8
70 7 0.98 68.64 -1.95
80 8 1.04 83.44 +4.3
90 9 1.00 90.45 +0.5
100 10 1.05 105.15 +5.15
(8) Calculation ofGas Exchange and Energy Expenditure
This was based on Pettenkofer's principle, illustrated by the equation:
Oxygen uptake V02 =
Flow into chamber, Vi
X
02 cone, in, Fi02
Flow out, Ve
X
02 cone, out, Fe02
The difference between Vi and Ve depends upon the respiratory quotient, the flow
rates used, and the volume of gas exchange. In the circumstances of this study the
difference amounts to .02 litres/min at the most, and Vi and Ve may be assumed to be the
same with little effect on calculated values of gas exchange (up to 5.9% error with the
smallest V02, the lowest flow rates used in this study, and an RQ of 0.7, see Appendix).
Thus a simplified equation can be used to obviate the need to measure Vi:
V02 = Ve (Fi02 - Feo2)
and Vco2 = Ve (Feco2 - Feco2)
A planimeter (Haff, model 315, Gebruder HaffGmBH, W Germany) was used to
measure areas under the curves of Feo2, FeCo2 and Ve, and hence derive averaged values
over short periods. It was calibrated before each set ofmeasurements, using known areas
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on graph paper. Once calibrated, errors in measuring areas of 100 sq. cm or more were
less than 0.1% as suggested by the manufacturer.
In calculating energy expenditure, it was chosen to ignore the protein contribution
to metabolism, and treat the total RQ as the non-protein RQ. The maximum possible
error in energy expenditure measurements arising from this assumption is 3.2% (see
Appendix).
2.1.6 Growth
Anthropometric measurements were made by the author, on at least 3 occasions
during the balance period, and where possible at follow-up. Each measurement was made
at the same time of day in a particular infant, and weights were always measured
immediately before a feed.
Weight: on Avery baby weighing scales to 5g.
Length: using a standard technique with a neonatal stadiometer
(Holtain Ltd, UK) to 1 mm.
Skinfold thickness: using skinfold callipers (Harpenden Ltd, UK), taking the
mean of three measurements at each site, always on the left
side to 0.1mm.
Biceps: I at the mid-upper-arm, midway between acromion
and Triceps: | olecranon processes.
Subscapular: immediately below the angle of the scapula.
Suprailiac: immediately above the posterior superior iliac spine.
Head circumference: the largest occipitofrontal circumference measurement of 3
obtained using a paper, non-elastic tape measure.
Mid-upper arm circumference:
the arm circumference midway between the acromion and
olecranon processes, with the same tape measure.
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Foot length: calcaneum to tips of toes
Forearm length: olecranon to fingertips
measured using a miniature
perspex gauge made for the
purpose (based on James
etal, 1979).
2.1.7 Statistical analysis
Statistical analysis was done using Statview software for Apple Macintosh
computers (SAS Institute Inc, USA) and SPSS software for PC (SPSS Inc, USA).
Correlation between two variables, and the proportion of variability explained,
was tested using the regression coefficient for linear and quadratic regression. The
difference between 2 groups was assessed using the non-parametric Mann Whitney U
test. Deviation of anthropometric data from the population norm was computed from
British Growth Reference data (Cole et al 1998) and software to calculate the z-score
(Child Growth Foundation, London).
2.2 BRONCHOPULMONARY DYSPLASIA For Results, see 3.2
For Discussion, see 4.2
These studies were carried out in the 3 years from 1989-1992. They were carried
out in the neonatal unit of the Royal Infirmary of Edinburgh, which is associated with a
maternity unit delivering about 6000 babies per annum, and providing a regional referral
service for perinatal care and neonatal intensive care for the South-East of Scotland.
2.2.1 Ethical approval and consent
The studies were approved by the Edinburgh Reproductive Medicine Ethics
Committee. Parents or guardians were fully informed about the study, and written
consent was obtained.
2.2.2 Study design
A prospective survey of the nutrient intake and growth of a consecutive cohort of
infants of birthweight less than 1500g, in one centre, was carried out over a 2 year period.
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During the first part of this period, methodology for measurement of energy balance and
bone mineral content was developed. Studies were subsequently carried out on
retrospectively selected nested subgroups of these infants in order to compare specific
aspects of nutrition in infants with and without BPD (see Fig. 2.4 below).
Fig. 2.4. Studies of BPD: study design
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2.2.3 Selection of cases
Criteria for inclusion were absence ofmajor congenital malformation or other
diagnosis which might affect nutritional status, and the availability of 3 weeks'
nutritional data and data on respiratory outcome. Babies with BPD were identified by the
need for supplementary oxygen at 28 days postnatal age to maintain an arterial oxygen
partial pressure of 6-10kPa or arterial oxygen saturation of 88-93% with X ray changes in
keeping with the diagnosis, and the absence of other respiratory diagnosis. Of the 195
babies, there were 29 deaths before 28 days, 7 babies for whom consent was not obtained
for any collection of data, and 50 babies for whom there was insufficient data because of
transfer to another hospital. Of the remaining 109 babies, 53 had BPD, and 56 did not.
2.2.4 Macronutrient intake and growth in bronchopulmonary dysplasia
All fluid intake was recorded prospectively in 195 consecutive very low birth
weight (VLBW, birthweight less than 1500g) infants daily for the first week and then
weekly until full term equivalent, or as long as the infant was still in the neonatal unit.
Fluid given (rather than that prescribed) was charted as volume of milk administered
measured by syringe, and volume of intravenous fluids delivered indicated on volumetric
pumps. No direct measurement was made of losses by vomiting or by leakage or
extravasation from intravenous lines. Nutrient intake was calculated from manufacturers'
data on nutrient composition and published data on the composition of expressed preterm
breast milk (Lemons et al 1982). The main reason for incompleteness of data was early
discharge to another unit after intensive care.
Babies had weekly detailed anthropometric measurement. This comprised weight
(to nearest 5g with averaging electronic scales [Mettler 515, Mettler Electronics Corp.
USA], with subtraction of known weights of equipment attached to the baby, e.g.
nasogastric tube, endotracheal tube and fixation), crown-heel length (to nearest
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millimetre with Holtain neonatal stadiometer), head circumference (to nearest mm with
paper tape measure), forearm and lower leg length (measured olecranon to distal ulnar
styloid and tibial tuberosity to medial malleolus, respectively, to nearest 0.1mm using RS
vernier callipers, RS components, UK, see Bishop et al 1990) and four skinfold
thicknesses (biceps, triceps, subscapular and suprailiac, to nearest 0.1mm with
Harpenden skinfold callipers). These measurements were done provided the baby was
judged sufficiently stable by medical and nursing staff responsible for their clinical care.
Babies were divided into those with and without BPD on the basis of continuing
requirement for supplemental oxygen, following neonatal respiratory disease, at 28 days
postnatal age. Each baby with BPD was then matched as closely as possible for gestation
and birthweight with control infants. Babies with a match for whom there was nutritional
data available for at least 3 weeks and data on respiratory outcome were included.
Feeding was by established protocols for clinical care and in individual babies
was decided by medical and nursing staff clinically responsible for them. Soon after birth
bigger babies who were in good condition (no respiratory distress, hypoglycaemia,
asphyxia or circulatory problems) were started on enteral feeds via nasogastric tube. Most
were initially given intravenous dextrose, later supplemented with electrolytes and
calcium when the need arose. Enteral feeds (as boluses via nasogastric tube) were started
as soon as the infant's general condition allowed, and provided there were no specific
contraindications (e.g. paralysis, high-placed umbilical artery catheter). Mothers were
encouraged to provide expressed breast milk for their own infant (this was given fresh or
after storage for up to 24 hours in a -4°C refrigerator or for up to 3 months in a -20°C
freezer), and when this was unavailable or insufficient, a preterm formula (SMA low
birth weight or Prematil) was given. Parenteral feeding was given when enteral feeding
had not been established in the first few days, earliest in the smallest infants. This
64
comprised Primene (Clintec, UK) as the protein source (Mcintosh and Mitchell 1990),
given to a maximum of 3.5g/kg/day and 10% Intralipid (Kabi Pharmacia, UK) giving up
to 3g/kg/day of fat. Fluid intake was increased from 75ml/kg/d by daily increases of
25ml/kg/d up to 150ml/kg/day, as allowed by clinical and biochemical assessment of
hydration, and provided there was no clinical problem related to the ductus arteriosus.
Further increases were made if needed to allow weight gain at about 15g/kg/day.
The macronutrient composition of formula feeds and parenteral nutrition
solutions was calculated from manufacturers' data and of preterm expressed breast milk







10% dextrose 167 0 0
Amino acid 188 2.4 0
10% Intralipid 460 0 10
Expressed breast milk 305 1.4 3.4
Prematil 293 2 3.5
SMA gold cap 272 1.5 3.6
Aptamil 280 1.5 3.6
SMA LBW formula 335 2 4.4
2.2.5 Energy balance and growth in bronchopulmonary dysplasia
Energy balance methodology was available for only the latter part of the research
period. Energy intake and losses, and body growth were studied in 4 babies with BPD
and 4 controls who were selected as a convenience sample of preterm infants less than 32
weeks gestation, distinct from the VLBW cohort. All studies were done at a postnatal age
of 3-8 weeks when the baby was on full enteral feeds and clinically stable. All BPD
babies were still receiving supplemental oxygen via ventilator, headbox or nasal cannula.
The methods used were essentially the same as those used for the study of babies
with congenital heart disease.
65
Although attempts were made to devise a system to measure energy expenditure
by indirect calorimetry in babies receiving supplemental oxygen or artificial ventilation,
technical problems highlighted by other workers (Kalhan and Denne 1990), precluded
this.
2.2.6 Bone mineral content in bronchopulmonary dysplasia
Bone mineral content was studied longitudinally in a subset of 54 babies within
the original cohort of VLBW infants (described in 2.2.4). The method used was dual
energy radiographic densitometry of the forearm using a portable X-ray machine
(Williams et al 1994, modified from Lyon et al 1989). Using this technique, weekly
measurements were taken of total bone mineral and bone mineral per unit length of the
ulna, when possible of the same forearm. In phantom studies, this technique has a
coefficient of variation of 7%.
Of the cohort of babies studied, it was possible to match 10 infants with BPD
with control infants, for gestation and birthweight, thus providing a nested cohort study.
The pattern of postnatal change in bone mineral content was compared in the matched
groups.
The effect of systemic corticosteroid treatment used for the treatment of BPD on
bone mineral content and linear growth was examined by comparing their postnatal
course in BPD babies separated into 2 groups depending on whether or not they received
dexamethasone. This was an exploratory study of the possible effect of dexamethasone
on bone mineral, and no sample size calculation was done. No attempt was made to
match cases and controls for this study, except for the diagnosis of BPD. Dexamethasone
was given to babies with BPD on clinical indication. The usual practice was to give it to
babies who were still ventilator-dependent at around 1 month of age, to help ventilator
weaning. It was started at a dose of 0.5 mg/kg/day and reduced over about 30 days (Avery
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et al 1985), the schedule being influenced by the severity of lung disease, clinical
response to steroid treatment, and the severity of any adverse effects.
In the group given steroids data were analysed for the 4 weeks before treatment,
and also during and up to 4 weeks after treatment. In the control group, the "treatment"
period was derived from the median times of starting and stopping treatment in the
steroid group. There were 15 infants with sufficient data (at least 2 measurements before
starting, and 2 during treatment) in each group.
2.2.7 Statistical analysis
Statistical analysis was done using Statview software for Apple Macintosh
computers (SAS Institute Inc, USA) and SPSS software for PC (SPSS Inc, USA).
Nutritional outcome variables were assumed to be distributed in a non-Gaussian
way and described using median and range or quartiles and groups compared using the
Mann Whitney U test. For comparison of longitudinal data between groups, separate
significance tests were carried out at each time point and the P value corrected for
repeated measures. Multiple logistic regression analysis was used to study the
independent predictive value of explanatory variables on particular outcomes. Deviation
of anthropometric data from the population norm was computed from British Growth




3.1 CONGENITAL HEART DISEASE For Methods, see 2.1
For Discussion, see 4.1
3.1.1 Subjects
Following an initial period of development and validation of methodology, case
recruitment was over a period of 18 months for the studies of intake and losses, and 1
year for energy expenditure. Hence, only a limited number of infants had a complete
energy balance study performed. A requirement for selection for the energy balance
studies was that infants were in hospital for at least 3 days, in a stable clinical condition.
This necessarily selected infants with certain types of heart disease. Gas exchange
measurements required a shorter period of study. Control infants were considerably more
difficult to recruit, as they had to be hospitalized, but well, infants. Most were previously
healthy infants recovering from some minor illness on a children's ward.
30 infants were included in the study; 21 with congenital heart disease, 9 controls.
Table 1. Energy balance in CHD: Studies and number of sub jects
Total no of Energy intake + Gas exchange Both parts of
infants losses alone alone study
(EI+EL) (EE) (All)
CHD 21 7 3 11
Control 9 0 4 5
The infants are described in Table 2, together with diagnoses and some of the
clinical features in cardiac infants. Several of the cardiac infants had cardiac
catheterization around the time of the study.
During the studies, none of the infants was acidotic or had serum electrolyte
abnormality. All remained clinically and biochemically stable except one infant with
ventricular septal defect who required increased drug treatment because of worsening
heart failure - this study had to be repeated.
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Table 2. Description of cardiac and control infants studied
Post¬ Post- Diagnosis Heart Cyanosis Pulmonary Studies
natal term failure hypertension




1 113 113 VSD + 0 + EI+EL
2 126 126 VSD, ASD + 0 0 EI+EL
3 21 14 VSD, ASD + 0 + EI+EL
4 121 121 VSD, PDA ligated,
PA banded
+ 0 + EI+EL
5 12 5 TGA, Rashkind 0 + 0 EI+EL
6 62 55 Tricuspid atresia,
PDA
0 + 0 EI+EL
7 43 22 Fallot's tetralogy 0 + 0 EI+EL
8 18 18 VSD + 0 0 All
9 103 103 Coarctation
repaired, mitral
stenosis
+ 0 + All
10 59 59 VSD + 0 0 All
11 75 75 Coarctation
repaired, VSD
+ 0 + All
12 50 43 TGA, Rashkind.
VSD, PDA
0 + 0 All
13 44 30 VSD + 0 0 All
14 246 246 VSD, aortic
stenosis
+ 0 + All
15 5 -9 TGA, Rashkind.
VSD, PDA
+ + 0 All
16 61 61 VSD + 0 ? All
17 104 69 VSD + 0 + All
18 44 44 Tricuspid atresia,
VSD
+ + 9 All
19 34 34 PDA + 0 0 EE
20 49 49 Tricuspid atresia,
VSD
+ + 0 EE
21 30 30 Coarctation
repaired, PDA,
double inlet RV
+ 0 0 EE
(a) Control infants
1 56 49 Upper respiratory
tract infection
All
2 42 0 Ex-preterm 34
weeks gestation
All
3 86 86 Feeding problem All
4 68 68 Upper respiratory
tract infection
All
5 56 -14 Ex-prem 30 weeks
gestation; URTI
All
6 73 73 URTI EE
7 35 35 Breath-holding
attacks
EE
8 5 5 Normal newborn EE
9 14 14 ?seizure EE
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3.1.2 Birthweight and Gestational age
Birthweight data were available from the birth records for the 5 hospitalized
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Gestational age (weeks)
Fig. 1. Gestational age and birthweight of study and control infants
All the control infants had birthweights between the 10th and 50th percentiles for
gestation. Of the cardiac infants, 3 were at about the 97th centile, and 3 were below the
3rd centile, the others being between these extremes.
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3.1.3 Age at study
Babies were studied at a postnatal age between 5 and 246 days, with a post-term
age of-14 to 246 days. Gestation at birth varied from 30 to 41 weeks.
Table 3. Post-term age of babies studied
median and
range
All babies Energy intake
+losses


















3.1.4 Weight as a proportion of expected weight, with age, in cardiac infants




























-100 100 200 300
Post-term age at study (days)




-20 0 20 40 60 80 100 120 140
Post-term age at study (days)
Fig. 3. Body weight standard deviation score and post-term age: cardiac
infants without outlier
This cross-sectional data suggests a 1SD drop, compared to population norms
every 21 days in body weight. By 120 days of age, babies were, on average, only 50% of
their expected weight, although only 3 of the babies were studied after this age. The worst
affected child was more than 8SD below the mean for weight. In Fig 3, an outlier of 246
days has been excluded. More than 80% of the variability of weight SDS was explained
by age.
3.1.5 Body length and head circumference with age in cardiac infants
Only those infants who were hospitalized for long enough to have EI and EL
measurements (18 CHD and 5 control infants) had complete anthropometry, hence this
information is available for only a proportion of the infants.
A postnatal fall off in centile level was also seen in these parameters, but to a
lesser extent than in weight. There was a 1SD reduction compared to population norms in
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length every 43 days, and head circumference every 37 days. However, only around 60%
of the variability in these measurements was explained by age.
Post-term age (days)
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Fig. 6. Body length standard deviation score and post-term age: cardiac infants
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3.1.6 Weight gain during balance study
The daily weight gain [median (quartiles)] of the cardiac infants [11 .Og (2.5-
16.7)] was less than that of the control infants [39.Og (20.0-47.5)], and that expected for
age. Some cardiac infants gained no weight. The difference was statistically significant,
P=0.0034, using the Mann-Whitney U test. There was a similar difference between the
two groups in weight gain/expected gain for age (Fomon et al 1971): cardiac 0.41 (0.10-
0.54) and control 1.11 (0.75-2.06), P=0.0017. 2 outliers in age in the cardiac group aged
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cardiac n=16 control n=5
Fig. 8. Weight gain during balance study as a proportion of expected gain,
comparing cardiac and control infants
3.1.7 Energy value of milks
The values obtained for heat of combustion by bomb calorimetry are shown in
Table 4, with, for comparison, values provided by manufacturers which are calculated as
the metabolizable energy of the constituents (Widdowson et al 1960).
Different batches of the same formula showed no significant difference in energy
content.
Table 4, Energy value ofmilks
Brand name Heat of combustion Calculated metabolizable
(kJ/lOOg) energy (kJ/lOOml)
Cow and Gate premium 305 285
Cow and Gate plus 305 272
Osterfeed 292 285
Ostermilk comp. 275 272
SMA goldcap 292 272




3.1.8 Daily intake of milk volume and energy
There was a wide spread of values with a large degree of overlap between the two
groups: for volume, Mann-Whitney U test P = 0.06; for energy intake, Mann-Whitney U
test P = 0.14 (Fig. 9, Table 5). When energy intake was expressed per kg 50th centile
weight for age, there appeared to be a bigger difference, but this did not reach statistical
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cardiac n=18 control n=5
Fig. 10. Daily energy intake for expected weight, comparing cardiac infants
with controls
3.1.9 Energy losses in urine and vomit
There was a wide inter-individual variation, with no significant difference
between the 2 groups: [median (quartiles)]: cardiac 27.4 kJ/kg/day (19.4-37.1), control
22.6 kJ/kg/day (18.9-31.7); Mann-Whitney U test, P = 0.54. One cardiac infant vomited
11% of feed intake, and 9/18 cardiac infants and 2/5 controls vomited 5-10% of intake. If
allowance is made for the systematic shortfall in energy yield by processing nappies and
bibs (11.8%), the largest correction to MEI would be about 6kJ/kg/day.
3.1.10 Energy losses in Stool
Energy losses in stool tended to decrease in both groups with age. Values varied
from 11.5 to 108.4 kJ/kg/d and 2.9 to 19.7% of energy intake. There was a large overlap
between cardiac infants and controls [median (quartiles)]: cardiac 45.2 kJ/kg/day (33.3-
62.2), control 73.6 kJ/kg/day (30.2-98.2); Mann-Whitney U test, P = 0.23.
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3.1.11 Metabolizable energy intake (MEI)
MEI was, in general, lower in cardiac infants, especially as a proportion of that
expected, but the difference did not reach statistical significance [values are medians
(quartiles)]: for cardiacs 417kJ/kg/d (348-451), for controls 455kJ/kg/d (405-548), Mann
Whitney U test P=0.22 (Table 5 and Fig. 11).



















1 400 260 11.5 10.5 378
2 670 376 36.2 19.8 615
3 557 476 50.3 28.1 418
4 391 179 34.7 17.8 337
5 471 469 61.8 53.5 357
6 637 435 81.9 26.4 529
7 510 342 53.4 37.0 420
8 501 520 37.3 29.9 435
9 418 236 34.1 41.1 345
10 383 292 31.1 38.0 315
11 593 325 52.4 36.6 492
12 556 377 24.5 18.3 513
13 368 305 57.2 20.7 307
14 481 188 19.1 15.2 445
15 397 418 78.3 26.0 291
16 516 402 63.6 35.2 416
17 401 234 40.1 26.7 422
18 484 282 65.7 37.3 381
Median 482 355 45.2 27.4 417
Control
1 649 552 39.2 22.6 590
2 549 392 73.6 18.4 455
3 510 445 88 19.4 403
4 454 414 21.2 24.1 408
5 654 398 108.4 39.3 506



















cardiac n=18 control n=5
Fig. 11. Metabolizable energy intake, comparing cardiac infants with controls
MEI as a percentage of recommended dietary allowance for age (RDA, DHSS,
1979) showed a positive correlation with weight gain during the study (Fig. 12); this was
statistically significant for cardiac infants, although MEI explained less than 30% of the
variability in weight gain (Fig. 12, r2 = 0.28; P = 0.024).
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Metabolizable energy intake %expected for age
Fig. 12. Metabolizable energy intake as % expected for age, and weight gain
On analysis of covariance, MEI %RDA and the presence of congenital heart
disease showed significant independent correlations with weight gain.




Coefficient Standard error P value
MEI %RDA 0.29 0.121 0.0262
CHD -20.663 5.122 0.0006
3.1.12 Sleeping oxygen uptake (SVn?), and resting energy expenditure
Measurements used for analysis of SV02 were for a minimum period of 30
minutes, and were all at least 1 hour after a feed. Resting energy expenditure (REE) was
calculated from a cumulative period of resting measurement of between 3 and 4 hours.
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Table 7. Sleeping oxygen uptake and respiratory quotient, and estimated values for daily energy
Baby Postnatal SV02 Mean MEI Resting Energy available
age(days) (ml/kg//min) sleeping (kJ/d) energy for deposition
RQ expenditure (MEI minus REE,
(REE, kJ/d) kJ/d)
Cardiac
8 18 7.49 .81 1761 1044 717
9 103 12.90 .81 1226 1721 -495
10 59 9.10 .84 1142 1038 104
11 75 13.88 .84 1418 1353 65
12 50 10.57 .78 1653 1031 622
13 44 11.09 .86 1172 1202 -30
14 246 12.70 .79 1464 1236 228
15 5 7.95 .84 1075 904 171
16 61 10.16 .80 1556 1131 425
17 104 9.45 .81 1452 986 466
18
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1 56 9.23 .89 2330 1276 1054
2 42 9.14 .82 1138 728 410
3 86 10.75 .77 1912 1377 535
4 68 8.75 .81 1845 1685 160



















SV02 (mls/min) and SV02 per kg body weight tended to increase with age. It was
particularly high in 3 of 4 infants with persistent cardiac failure and pulmonary
hypertension (pht, see Fig. 13). SV02/kg correlated inversely with measures of body fat
(summed skinfold thicknesses, SSFT, and body mass index, BMI). SSFT showed an
exponential relationship to SVo2/kg and log SSFT showed a stronger correlation with
SVo2/kg: r2=0.671; P=0.0001 (Fig. 14). SV02 correlated with estimated metabolic body
size (weight374 and weight172) for control infants (r= 0.86, PO.Ol), but not for cardiacs
(r=0.37).
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On multiple regression analysis, SV02 for all babies correlated independently with
weight, estimated metabolic weight, and log (summed skinfold thicknesses). In this
analysis, postnatal age and the presence ofCHD were not independent predictors of SV02
(Table 8).
Table 8. Independent predictors of sleeping oxygen uptake in cardiac and control infants
Independent coefficient Standard error P value
correlations with
SV02
Study weight 0.011 0.002 0.0001
log SSFT -34.5 9.67 0.0044
Postnatal age 0.025 0.021 0.27
CHD 0.94 1.89 0.63
Sleeping respiratory quotients (mean +/-sd) were similar in the 2 groups (CHD
0.81 +/- 0.04; control 0.83 +/- 0.03). Resting energy expenditure showed a large overlap
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Fig. 13. Change in sleeping oxygen uptake with age
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3.1.13 Energy available for deposition (EAD)
EAD, which is a component of the energy cost of growth, was extrapolated for
those infants who had a complete study performed, as: (MEI - REE). It should be noted
that REE will be lower than total energy expenditure, and therefore EAD is likely to be
an overestimate. EAD showed a large inter-individual variation with considerable overlap
between study and control groups, but there was a positive correlation between EAD and
weight gain. Note that the intercept of the regression line is significantly different from
zero (Fig. 15). There appears to be an outlier, with a negative value for EAD and no
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Energy available for deposition (kJ/d) Excluding apparent
outlier (\>), Rsq = 0.4250
P = 0.08
Fig. 15. Relationship between energy available for deposition and weight gain
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3.2 BRONCHOPULMONARY DYSPLASIA For Methods, see 2.2
For Discussion, see 4.2
3.2.1 Macronutrient intake and growth
(i) Subjects
Of the 195 infants in the consecutive VLBW cohort, 49 babies developed BPD.
There were 20 infants with BPD and 20 matched controls with sufficient data.
Table 9. Description of BPD and control infants
median and range BPD (n=20) Control (n=20)
Gestation (weeks) 29 29
(26-30) (26-31)
Birthweight (g) 1140 1225
(905-1426) (825-1485)
Duration of ventilation 15 1.5
(days) (2-55) (0-5)
Duration of supplemental 53 2.5
oxygen requirement (days) (31-110) (0-7)
Postnatal steroid therapy 6 0
Post-conceptional age at 39.4 35.5
discharge (weeks) (33.0-40.9) (30.0-40.3)
(ii) Macro-nutrient intake
The total intakes of energy, fat, and protein from enteral and parenteral sources
were compared in the 2 groups for the 24 hours at the end of each week (for the first 8
weeks) after birth. Although data was available for longer in some babies, only 8 weeks
of data have been analysed since after this time an increasing amount of data is missing
because of discharge of babies. Mean daily intake for the 1st week was also compared




Energy intake was lower in BPD infants in the first 2 weeks of life, most
strikingly for total 1st week intake, for which the difference between medians was 85.8
kJ/kg/day.
Table 10. Daily energy intake (enteral and parenteral) in BPD and control infants
ENERGY INTAKE BPD Control Mann-Whitney U test:
(kJ/kg/d) n=20 n=20 P value (with
median and quartiles Bonferroni correction
for 10 tests)
1 st week daily mean 262 347 0.0003
(210-282) (293-372) (0.003)
end of week 1 408 494 0.0001
(310-448) (435-519) (0.001)



































P<0.05 * before correction
for multiple tests
** after correction

























BPD n=20 control n=20
Fig. 17. Mean daily energy intake in first week, comparing BPD and control
infants
(2) Fat intake
Fat intake was markedly lower in BPD infants when analysed for total intake in
the first week and lower (though not reaching statistical significance after correction for
multiple tests) at the end of the first week. Differences between medians were 2.15 and
1,36g/kg/d respectively.
Table 11. Daily fat intake (enteral and parenteral) in BPD and control infants
FAT INTAKE BPD Control Mann-Whitney U test:
(g/kg/d) n=20 n=20 P value (with
median and quartiles Bonferroni correction
for 10 tests)
1st week daily mean 1.73 3.88 0.0001
(0.92-2.58) (3.03-4.16) (0.001)
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BPD n=20 control n=20
Fig. 19. Mean daily fat intake in first week, comparing BPD and control infants
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(3) Protein intake
The only significant difference in protein intake (before correction for multiple
tests) was in the total first week intake, with a difference between medians of 0.42g/kg/d.
Table 12, Daily protein intake (enteral and parenteral) in BPD and control infants
PROTEIN INTAKE BPD Control Mann-Whitney U test:
(g/kg/d) n=20 n=20 P value (with
median and quartiles Bonferroni correction
for 10 tests)














































BPD n=20 control n=20
Fig. 21. Mean daily protein intake in first week, comparing BPD and contrc
infants
(4) Enteral feeds
Enteral intake contributed significantly less to total energy intake in the first two
weeks of life in infants who later developed BPD. At the end of the second week of life
all control infants and 16 of 20 BPD babies were receiving full enteral feeds.




























(iii) Growth pattern in neonatal period
BPD infants gained weight at a slower rate after the first week than controls.
Growth rates (slopes and 95% CI) were 151.5 g/week (135.5-167.6) for babies with BPD
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Fig. 22. Weight gain with age, comparing BPD and control infants
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There was no apparent difference between the groups in growth in forearm







Fig. 23. Gain in forearm length with age, comparing BPD and control infants
(iv) Growth attainment at discharge
There was a large overlap between the groups in weight standard deviation score
at discharge [median (quartiles)]: BPD = -0.71 (-1.20 to -0.11) and control -0.87 (-1.89 to
-0.37).
Crown-heel length, head circumference and body mass index (weight in
grams/[height in mm]2 x 100) at discharge increased as expected with post-conceptional
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1 30 1715 1.42 f 50 2519 -0.75
2 27 900 -0.47 f 44 1314 -2.72
3 29 765 -2.32 f 92 2539 -0.18
4 23 712 1.86 f 46 1221 -0.84
Median
BPD
28 832 0.48 48 1916 -0.79
Control
1 24 745 0.42 m 44 1055 -2.31
2 28 905 -1.01 f 29 1532 -2.52
3 29 825 -2.27 m 23 1156 -4.15
4 28 1255 0.81 f 34 2128 -0.74
Median
control
28 865 -0.32 32 1344 -2.41
There was a difference in postnatal age between BPD babies and controls. This is
because, although babies were identified at 28 days as having BPD, an attempt was made
to study these babies once they had significant established chronic lung disease. It was
unusual for control infants to still be hospitalized at this stage. None of the babies with
BPD received steroid treatment.
(ii) Energy intake and losses There was no significant difference between
groups in energy intake, energy losses in stools, urine or vomitus, or in metabolizable
energy intake (Mann-Whitney U test).
Table 16. Energy balance in BPD: energy intake and losses, and weight gain
median and range BPD Control
Daily weight gain (grams) 35.1 (17.7-39) 26.5 (15-55)
Energy intake (kJ/kg/day) 633 (502-812) 647 (611-808)
Energy losses in stool (kJ/kg/d) 47 (21-59) 63 (50-67)





592 (425-741) 565 (527-737)
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3.2.3 Bone mineral content
(i) Postnatal course
For the cohort of babies who had bone mineral measurements (n=54), BMC at
birth [median (quartiles)] was 1.79mg/mm (1.57-2.03), with a fall in the first 5 weeks of
0.23mg/mm (0.09-0.41), followed by a rise, with a value at 10 weeks of 1.99mg/mm
(1.69-2.16). In Fig. 28, the postnatal course ofBMC is shown as a change from the value
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Fig. 28. Change in bone mineral content with age: all babies
97
(ii) Effect of BPD
Bone mineral content (BMC, mg/mm of bone length) was compared in 10 BPD
and 10 control infants matched as closely as possible for gestation and birthweight.
Table 17. Bone mineral content in BPD: description of infants
Subjects BPD Control
Gestation (weeks) 29 29
median and range (28-30) (28-30)
Birthweight (g) 1179 1187
median and range (980-1253) (1140-1263)
Sex 4 f; 6 m 7 f; 3 m
Steroids 3 infants 0
The postnatal course of bone mineralization in the two groups is shown in Fig. 29.
There was a steady drop in BMC to about 6 weeks of age, followed by a more rapid rise.
There was no significant difference between the groups in the postnatal course of
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Fig. 29. Change in bone mineral content with age, comparing BPD and control
infants
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(iii) Effect of Dexamethasone
15 infants treated with dexamethasone for bronchopulmonary dysplasia (treatment
given for clinical indications to help weaning from ventilator support, Avery et al 1985),
median (range) gestation 27 (26-29) weeks were compared with 15 other infants with
BPD, median (range) gestation 27 (25-31) weeks. Some measurements were not done
when a baby was considered too unstable, or later because of discharge from the study
hospital.
Pre-treatment values were:
Table 18. Bone mineral content in BPD: pre-treatment values

















Subsequent values were expressed as a change from immediate pre-treatment
values (change in bone mineral content, dBMC; change in forearm length, dFAL).
There was no difference in dBMC between the groups at any stage (Fig. 30).
There was an increasing difference in dFAL between the BPD and control groups
which just reached statistical significance in the week after completion of steroid
treatment (Mann Whitney U test, see Fig. 31 and Table 19).
Table 19. Bone mineral content in BPD: change in bone mineral content and forearm length with
dexamethasone treatment
median and range Steroid-treated Control Mann-Whitney U test:
P value (with Bonferroni
correction for 9 tests)
dBMC (mg/mm) n=10 n=6 NS
+0.22 +0.24
(0.02-0.69) (0.11-0.44)
dFAL n=13 n=l 1 0.019
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4.1 CONGENITAL HEART DISEASE For Methods see 2.1
For Results see 3.1
4.1.1 Summary of findings
The current work comprises descriptive studies of hospitalized children with
congenital heart disease in comparison with controls. It suggests that these children are
within the normal range in size at birth, but subsequently accumulate a deficit in weight,
length and head size. In association with this, infants with CHD appear to have a lower
range of total and metabolizable energy intakes (although this was not statistically
significant), with a positive correlation between MEI as a percentage of RDA (a measure
of the appropriateness of energy retention for age) and weight gain in infants with CHD.
There is increased resting energy expenditure (when expressed per kg body weight) in
some infants with CHD, and REE is inversely related to measures of body fat.
4.1.2 Implications for clinical practice
The pattern of increasing postnatal deficit in body size suggests an external
influence, probably undernutrition, although some basic abnormality of metabolic
adaptation taking effect postnatally is not ruled out by the current work. The correlation
demonstrated between (metabolizable) energy intake and growth rate suggests that
retention of energy is a limiting factor for growth in infants under 8 months of age with
CHD. Some infants are in "double jeopardy" because an elevation in energy expenditure
means an even greater intake needed to provide for growth.
Although there is no randomised controlled study looking at the influence of
aggressive nutrition on important clinical outcomes in CHD, there is considerable
indirect evidence of benefit and lack of harm. Good nutritional intake and optimal growth
should be major goals in the care of infants with CHD. Early consideration should be
given to fortification of feeds and supplementary intragastric feeding in infants who have
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demonstrated a significant fall in centile level, the target being catch-up growth. This
may be particularly important in infants with cardiac failure because of the temptation to
restrict fluids. Research following on from the current work, in the same centre, suggests
that increased energy intake can result in a useful improvement in energy retention,
although resulting in less catch-up growth than would be expected from the increased
metabolizable energy. This suggests either that (a) this additional intake is metabolised as
a fuel source, perhaps because insufficient protein was given to allow utilization of
energy for growth, or that (b) diet-induced thermogenesis was increased, or that (c) these
infants had a higher energy cost of weight gain because of a different tissue composition
(Jackson and Poskitt 1991).
4.1.3 Critique of current work
The present study is important because it provides quantitative and detailed
information about all components of energy balance and relates this to short-term growth
in infants with congenital heart disease within a narrow age range. Another strength is
that an attempt has been made to make comparison with healthy controls using the same
methodology. It appears to have been the first study to achieve these aims, at least in a
limited way. Although modern stable isotope methods enable the assessment of energy
requirements from accurate measurements of TEE, energy balance cannot be so fully
compartmentalized as with the methods used here.
The limitations of this work are that (1) it is a descriptive study without
calculation of sample size, (2) the number of cases is relatively small, with a particular
shortage of control infants; thus there is a greater possibility of results representing the
effect of chance or insufficient numbers, with the resultant risk of drawing erroneous
conclusions, (3) the sample selected is probably not representative of (that is, generally
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sicker than) the total population if infants with CHD, thus limiting the generalizability of
the results.
In common with studies of nutrient balance, in general, there appears to be a
systematic shortfall in energy retrieved from collection of losses. However, correcting for
the underestimation measured in the quality control experiments has an insignificant
effect on ME1, and does not affect the conclusions drawn here.
There are particular problems with the interpretation of energy expenditure
measurements: (1) There are errors in extrapolating total energy expenditure from
measurements of resting oxygen consumption. The energy expenditure of an individual
varies greatly with time, and even 24-hour measurements may not adequately represent
typical values. In addition, the energy consumed during feeding has not been measured in
this work, and there may be a significant difference between the groups. (2) There is a
large biological interindividual variability in energy expenditure measurements even in
an apparently homogeneous group of infants under standard conditions (Denne and
Kalhan 1986). This reduces the likelihood of detecting an important difference between
groups unless large sample sizes are used.
It should be remembered that, where energy intake has been related to expected
intake, recommended dietary allowances (RDA) have been used which have been revised
since these studies were carried out. The current values for RDA, being about 10%
lower, imply a smaller shortfall of MEI in the subjects of the current study than implied
by the results as presented here. However, this does not significantly affect the
relationship between the CHD and control groups, or the correlation between MEI%RDA
and weight gain.
The strong inverse correlation between sleeping V02 and measures of fatness
might be explained in one of several ways: (1) lack of body fat in thin infants is a direct
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consequence of increased energy expenditure not being matched by a commensurate
increase in intake, (2) when energy expenditure is expressed in relation to body weight, a
larger proportion of this weight is metabolically active lean tissue in undernourished
infants with the highest expenditure, (3) in thin infants, hypermetabolism may merely be
an adaptation to greater heat loss. Recent studies showing a dramatic drop in total energy
expenditure soon after corrective or palliative surgery suggest that physiological changes
linked to the basic anatomical abnormality, rather than a basic metabolic defect, are to
blame for the increased metabolic rate in these infants (Mitchell et al 1994). The less
good correlation, in infants with CHD than in controls in the present study, between
SV02 and measures of metabolic body size again suggests that in CHD REE is strongly
influenced by factors other than body size. There is, of course, a question mark over how
well derived values (such as weighty4, Kleiber 1961 and weight'72, Davies et al 1989)
represent metabolic body size in infants with CHD, because they have not been validated
in this group, and also because of the possibly greater water content of lean body tissue
in some infants with CHD (Mitchell et al 1995).
An attempt has been made to derive the energy available for deposition in the
current study. Apart from errors in the extrapolation of total energy expenditure,
comparing the energy available for deposition in different populations assumes that the
composition of tissue gain, and hence the energy cost of growth, is always the same. This
may not be true in clinically different populations, at different ages, and at different rates
of weight gain as (a) the stored energy values of protein and fat are very different (5.65
vs 9.25kcal/g) and (b) the energy required for tissue accretion is greater for protein than
for fat (7.8 vs 1.6kcal/g) (Roberts and Young 1988).
Can the explanations for altered energy balance in other chronic diseases such as
cystic fibrosis help to elucidate what is happening in CHD? In cystic fibrosis, as appears
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to be the case in CHD, the insufficiency of intake to maintain a sufficiently positive
energy balance for growth is contributed to both by a limitation of intake and by an
increase in expenditure. In both conditions, the raised REE is probably partly related to
increased respiratory and cardiac work. A chronic inflammatory process is certainly a
feature of chronically ill children with cystic fibrosis, and evidence for this has been
found in adults with chronic cardiac failure, with a correlation between markers of
inflammation and energy expenditure. No published work has been found looking at the
inflammatory process in CHD. Interestingly, in cystic fibrosis and in acquired immune
deficiency syndrome, despite a raised REE, TEE is not increased because of a reduction
in energy expended in activity. No conclusion can be reached about activity in CHD
because neither TEE nor any measure of activity was obtained in this study. However, it
is unlikely that changes in activity level, which contributes a very small proportion of
daily energy use at this age, could fully compensate for the hypermetabolism seen in
some babies in this study.
4.1.4 Suggestions for further research
In order to try to improve the nutritional outcome for infants with CHD (that is to
improve nutritional status until surgery can be performed) more detailed studies of
energy and protein turnover need to be carried out, probably using stable isotope
technology. Nutritional interventions need to provide the optimal balance of protein and
energy. The quality of weight gain should be studied using stable isotope and other
methods of studying body composition, having derived validation equations for this
particular population of sick children.
Most useful will be studies looking at major outcomes (survival, time to surgery,
and incidence of postoperative complications including infection) with aggressive
compared with conventional nutrition. The data in the present study, suggesting
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progressive postnatal undernutrition of early onset, may justify starting such an
intervention at diagnosis in the most at-risk patients.
Systemic inflammatory responses should be studied in infants with CHD since
there appears to be a strong association between inflammatory markers and nutritional
impairment in adults with cardiac failure, and this may generate the possibility of
therapeutic interventions.
4.2 BRONCHOPULMONARY DYSPLASIA For Methods, see 2.2
For Results, see 3.2
4.2.1 Summary of findings
In the current work several measures of nutritional status were compared in
babies who went on to develop BPD and controls who did not. In BPD babies, prior to
development of established chronic lung disease, macronutrient intake was significantly
less in the first week for energy, fat and protein, and a greater proportion of nutritional
intake in the first two weeks was by the parenteral route. This was associated with a
significantly slower weight gain in these infants in the first few weeks. There was no
detectable difference in energy intake or losses or in MEI between babies with
established BPD and control infants at 3-8 weeks postnatal age. There was a trend for all
babies to accumulate a postnatal deficit in bone mineral content for the first 5 weeks with
a subsequent slow increase, but leaving a large deficit at full term equivalent.
The postnatal trend of forearm bone mineral content and linear growth were not
demonstrably affected by the presence of BPD. The use of dexamethasone in BPD
appeared to slow linear growth of the forearm without any measurable effect on bone
mineral.
4.2.2 Implications for clinical practice
Because of the association between early undernutrition and BPD and the
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plausibility of an aetiological link, clinicians should aim to maximize nutritional intake
as part of the routine early management of babies at high risk of developing BPD. This
should include consideration of the early use of parenteral nutrition with lipid, and the
avoidance of unnecessary delay in introducing milk feeds, unless there are specific
contraindications. There is little rationale in limiting fluid intake routinely in BPD, unless
a baby is very sick, and in that case powerful diuretics are likely to be used. There is also
a case for early treatment of persistent ductus arteriosus with its tendency to increase
lung fluid, thus obviating the need for symptomatic treatment such as fluid (and hence
nutritional) restriction or the chronic use of diuretics. The significant deficit in bone
mineral accumulated by the VLBW babies by full term equivalent in this study, although
not shown to be different in babies with BPD, may contribute to respiratory difficulty in
all babies by creating inefficiency of chest wall movement. Insufficient data are available
at present to justify the chronic use of diuretic treatment, which has the potential for
creating further mineral depletion (Brion et al 2002).
4.2.3 Critique of current work
The current work is informative in providing some insight into the possible
aetiological link between early undernutrition and BPD, which has previously been
strongly suggested by animal studies. It also contributes to the literature on nutritional
status in established BPD. The limitations are that (1) the studies are retrospective and
observational, increasing the likelihood of confounding factors influencing the results,
and (2) the sample size in all these studies is relatively small (particularly the study of
energy balance) with no power calculation, raising the possibility of a Type II statistical
error.
An early nutritional deficit is associated with poor early weight gain in BPD,
although in the current work there is no evidence that body size attainment at discharge is
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affected. Early undernutrition may contribute to the pathogenesis of BPD because of
increased oxygen toxicity and slow lung healing. Differences in energy and fat intake
may, in this situation, merely be markers for more important differences in micro-
nutrient intake, for example of the fat-soluble vitamins A and E which are thought to be
important in lung protection and healing. The current results are consistent with the
findings of Wilson et al (1991) who performed a similar case-control study matching for
gestation alone, and found, in addition, that babies with BPD were smaller for gestation
at birth.
Babies with BPD appear to demonstrate poor weight gain for the first few weeks
without an obvious ongoing shortfall in intake, although there is no evidence that this
results in a deficit in size at discharge. In contrast to these results, Embleton et al (2001)
showed that in their unit infants of gestation less than 32 weeks continue to accumulate a
deficit in energy and protein intake (compared with recommended dietary intakes) for
several weeks postnatally, in association with a sustained deficit in weight z score. The
nutrient deficit explained 45% of the variation in weight. Other possible explanations for
ongoing growth failure are (a) a persistent inflammatory process fuelling a
hypermetabolic state with a resultant requirement for a greater than normal energy intake
(b) chronic hypoxaemia.
The greater proportion of feeds given parenterally in BPD babies may purely be
the reflection of the approach to management of a sicker group. However, could it be a
reflection of a beneficial effect of nutrients in milk on lung protection (because of better
bioavailability of protective agents)? Conversely, could it be an adverse effect of the use
of parenteral nutrition? One candidate for the latter is lipid toxicity; the other is the
greater likelihood of nosocomial infection (with its association with BPD, Gonzales et al
1996) in babies fed parenterally.
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In the small comparative study reported here of energy balance in infants with
established BPD and controls, there are limitations in the comparability of the groups.
The control infants were smaller for gestation at birth, and younger and smaller for age
when studied. There was no detectable difference in energy intake or energy retention.
Thus the explanation for poor growth, when seen in babies with BPD, may be more
likely to lie either in hypermetabolism related to the disease process or a difference in the
energy needs for tissue deposition. A recent study (Boehm et al 1996) showed increased
fat excretion in the stool (with a reduction in duodenal lipase production) and reduced
weight gain in infants with BPD compared to other preterm infants. They found, as in the
present study, a greater use of the parenteral route for nutrition in babies who developed
BPD, and suggested that this could have led to a slower maturation of pancreatic lipase
production and less bile acid release because of cholestasis, resulting in a greater degree
of fat malabsorption. The authors also point out that steroids enhance pancreatic function
-none of the babies in this study received steroids during or prior to energy balance
measurements. In the babies studied here, the range of stool energy was, if anything,
lower in babies with BPD. This could have been an effect of age as the BPD babies were
older than the controls in this small group.
It was not possible to accurately measure energy expenditure by indirect
calorimetry in babies needing supplemental oxygen with the technology available at the
time of this study. The alternative would have been to perform these measurements once
oxygen therapy was discontinued. Such a study would have shown whether there was a
persistent hypermetabolic state in BPD, but left considerable uncertainty about energy
expenditure during the period when lung disease was at its worst and when growth is
most impaired.
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The one intervention study which has looked at the influence on clinical
outcomes of aggressive nutritional input did not show any effect on the incidence of
chronic lung disease (Wilson et al 1997). However, there are several reasons why this
should not be thought of as a definitive answer to the question of nutrition in the
aetiology of chronic lung disease: (1) chronic lung disease was not defined as the main
outcome in this study; (2) it may not have been sufficiently focussed on a group at
significant risk of chronic lung disease -the definition used was the need for added
oxygen at 28 days postnatal age, an endpoint which was probably too crude and
potentially influenced by many inexact clinical factors: it occurred in nearly half the
babies in both groups; (3) the intervention was complicated and arguably not aggressive
enough in terms ofmacronutrient intake, only achieving 1 OOkcal/kg/day total intake after
7 days, and in terms of enteral intake, taking a median of 21 or 22 days (and a minimum
of 13 days) to reach full enteral feeds (compared with a median of 9 days in our unit
during this study); (4) there is the possibility that the higher intravenous lipid intake in
the intervention group had the effect of worsening pulmonary outcome, thus confounding
the results; (5) the higher illness severity of babies in the intervention group may have
predisposed this group to adverse outcomes, obscuring a beneficial effect of aggressive
nutrition.
In our VLBW subjects, a large deficit in BMC continues to be accumulated for
about the first 6 weeks, long after these babies have established a constant enteral intake.
This, together with a slow subsequent rate of accretion, resulted in a mean BMC similar
at full term equivalent to that at birth. This leaves a substantial deficit since 80% of foetal
bone mineral accretion normally occurs in the 3rd trimester. Others have described a
similar deficit (Lyon et al 1989), although there have been reports of achievement of
intrauterine rates of mineralization with supplemented feeds (Chan et al 1988). In theory,
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osteopenia might be more likely in babies with BPD because of poor early intake
exacerbated by the use of loop diuretics and steroids. The lack of any detectable
difference in the postnatal course of bone mineralization in infants with and without BPD
is in agreement with the results of Greer et al (1987).
Dexamethasone was being used commonly in our unit at the time of this study.
Although there are theoretical reasons for concern about bone growth and mineralization
with steroid treatment, only a slight slowing of linear growth was demonstrated.
There is the possibility that confounding factors associated with the occurrence of
BPD and with the use of steroids influenced the results of the studies of BMC. However,
confounders such as poor early nutritional intake would have been expected to act to
reduce bone mineral in the study group compared with the controls, as the BPD babies in
the first study and the steroid-treated babies in the second are likely to have been sicker
and at greater risk of undernutrition. However, it is possible that the limits of sensitivity
of the technique for measuring bone mineral content, as well as inter-individual variation,
may have masked a real difference between the groups in these studies. Other reasons for
caution in interpreting these results are (1) it has become accepted practice, since this
work was done, to correct values of total body BMC for body size because this has a
strong independent influence on bone mineral content (Prentice et al 1994) -correction
for body size in the current study would have led to relatively higher values in BPD
(smaller size) than in controls (2) only localized assessment of BMC was made (there
were not the facilities for measuring total body BMC), and these may not be
representative.
Even though none of the steroid-treated babies developed acute complications
such as overt glucose intolerance, significant hypertension, or systemic sepsis, caution
should be used in interpreting the present results as suggesting that dexamethasone is a
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safe drug. There are metabolic concerns about linear growth, and protein catabolism
(Bloomfield et al 2001). In addition, the more recent discovery of an association between
the use of dexamethasone and adverse neurodevelopmental outcome has led to serious
questioning of the place of neonatal steroid treatment (Barrington 2001).
Since the current work was done, the incidence of severe ("old") BPD appears to
have reduced considerably. This is probably the result of better obstetric and early
neonatal care, including the more routine use of antenatal steroids in preparation for
preterm delivery and the early use of surfactant, reducing the need for damaging
respiratory support. However, there is now the phenomenon of "new" BPD, seen
predominantly in babies of less than 1kg, who have had only modest early lung disease.
This may be partly caused by nutritional deficiency, a possible model for this being the
small for gestation preterm infant who has experienced intrauterine undernutrition and
has a higher than gestation-related risk of chronic lung disease which is not associated
with early severe lung disease (Lai et al 2003).
4.2.4 Suggestions for further research
There is good reason to believe that poor early nutritional intake is an aetiological
factor in BPD. The published evidence suggests that feeding practice in preterm infants is
very variable. Extremes of current approach are likely to pose serious but conflicting
threats. Further well-designed randomized controlled clinical trials are needed,
comparing different feeding strategies, with sufficient statistical power to detect
differences in important outcomes. Two areas should be a priority: (1) studies of
aggressive compared with cautious use of parenteral nutrition, looking at chronic lung
disease as the main outcome in babies of <1 kg birthweight, and (2) studies of rapid
compared to slow introduction of enteral feeds, with necrotizing enterocolitis and
nosocomial (especially line-related) infection as end points.
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Interventions aimed at reducing the postnatal deficit in bone mineral should be
assessed, including mineral supplementation, and studies of the clinical risks and benefits
of diuretic use in BPD.
Longer term nutritional interventions should be studied, aimed at normalizing
post-term growth rate and body composition. Studies of dietary supplementation should
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Appendix
THE EFFECT OF ASSUMING VI=VE
1 V
Vi \ > Ve
Fio2 CO2 output Feo2
Fico2 O2 uptake Feco2
Ve = Vi - O2 uptake + CO2 output
O2 uptake = RQ
CO2 output
The greatest difference between Vi and Ve will be when there is an RQ furthest from 1, i.e.
0.7, and when the flow rate is at its lowest. The lowest flow rate (Vi) used is one resulting in
an mixed-expired CO2 concentration of 0.5%.
Take the extremes of V02 in our studies, with an RQ of 0.7.





















Accurately, VCo2 = Ve FeCo2 - ViFiCo2
Ve - VC02 + ViFico2
Feco2
and Vi = Ve + V02 - Vco2 (from above)
Assuming ViFico2 to be negligible (Fico2 v. low), Ve and Vi can be calculated (see table). V02
and VCo2 (assuming Vi = Ve) can then be calculated, and the error involved ascertained.
Feo2 is calculated from:
Feo2 = ViFio2 - (Vco2/0-7)
Ve
THE EFFECT OF IGNORING THE PROTEIN CONTRIBUTION TO OXIDATIVE
METABOLISM ON THE CALCULATION OF ENERGY EXPENDITURE
The non-protein RQ allows for the protein contribution to oxidative metabolism when
calculating energy expenditure. When the total RQ is used instead, we are assuming that the
protein contribution is 0.
Total RQ — Vco2 / V02
Non-protein RO = VC02 - Vc02prot / V02 - V02prot
Vco2prot and Vo2prot are derived from urinary protein excretion.
When protein contribution = 0, non-protein RQ = total RQ.
Example Baby with V02 50ml/min
Calculate RQ from proportions and kcal equivalents using Weir's formula for
protein and non-protein components.










tot RQ kcal/min tot RQ kcal/min tot RQ kcal/min
No CHO 0.707 0.2343 0.714 0.2326 0.732 0.2348 0.21%
CHO+fat
50:50
0.859 0.2430 0.852 0.2379 0.844 0.2379 2.14%
No fat 1.00 0.2524 0.973 0.2485 0.947 0.2445 3.23%
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For column 25% protein energy
25% protein energy ~ 26.8% protein 02
For row No CHO Fat RQ = 0.707 Protein RQ = 0.802
Total RQ = .732
V02 =50ml/min; Vco2 = 50 x 0.732 = 36.6ml
V02prot = 26.8 x 50/100 = 13.4ml
Since RQprot = 0.802, VCo2prot = 13.4 x 0.802 = 10.74ml
Non-prot V02 = 50 - 13.4 = 36.6ml
Non-prot VC02 = 36.35 - 10.74 = 25.76ml
Non-prot RQ = 25.76ml / 36.6ml = 0.7038
= 4.68kcal/l 02 (Zuntz table)
= 4.68x 36.6ml = 0.1712kcal
non-prot energy/min
Add protein contribution = 13.4 x 4.46 = 0.0597kcal
TOTAL Energy Expenditure = 0.1712kcal + 0.0597kcal
= 0.2348kcal/min
For row CHO+fat 50:50
RQ 50:50 CHO:fat =.859; RQ protein =.802
Total RQ = .844
V02 =50ml/min; Vco2 = 50 x 0.844 = 42.2ml
V02prot = 26.8 x 50/100= 13.4ml
Since RQprot = 0.802, VCo2prot = 13.4 x 0.802 = 10.746ml
Non-prot V02 = 50 - 13.4 = 36.6ml
Non-prot VCo2 = 42.2ml - 10.74 = 31.46ml
Non-prot RQ = 31.46ml / 36.6ml =0.859
= 4.87kcal/l 02
S 4.87 X 36.6ml = 0.1782kcal
non-prot energy/min
Add protein contribution = 13.4 x 4.46 = 0.0597kcal
TOTAL Energy Expenditure = 0.1782kcal + 0.0597kcal
= 0.2379kcal/min
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For row No fat CHO RQ = 1.000 Protein RQ = 0.802
Total RQ = 0.947
V02 = 50ml/min; VC02 = 50 x 0.947 = 47.34ml
V02prot = 26.8 x50/100= 13.4ml
Since RQprot = 0.802, Vc02prot = 13.4 x 0.802 = 10.74ml
Non-prot V02 = 50 - 13.4 = 36.6ml
Non-prot Vco2 = 47.34 - 10.74 = 36.60ml
Non-prot RQ = 36.6ml / 36.6ml = 1.000
= 5.05kcal/l 02 (Zuntz table)
= 5.05x 36.6ml = 0.1848kcal
non-protein energy/min
Add protein contribution = 13.4 x 4.46 = 0.0597kcal
TOTAL Energy Expenditure = 0.1848kcal + 0.0597kcal
= 0.2445kcal/min
For column 12.5% protein energy
12.5% protein energy a 13.4% protein 02
For row No CHO Fat RQ = 0.707 Protein RQ = 0.802
Total RQ = 0.720
V02 =50ml/min; VCo2 = 50 x 0.720= 35.98ml
VO2pr0t= 13.4x 50/100 = 6.7ml
Since RQprot = 0.802, VCo2prot = 6.7 x 0.802 = 5.37ml
Non-prot V02 = 50 - 6.7 = 43.3ml
Non-prot VCo2 = 35.98 - 5.37 = 30.61ml
Non-prot RQ = 30.61ml / 43.3ml = 0.7069
= 4.686kcal/l 02 (Zuntz table)
= 4.686 x 43.3ml = 0.2029kcal
non-prot energy/min
Add protein contribution = 6.7 x 4.46 = 0.0298kcal
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